--- a
+++ b/clusters/3009knumclusters/clust_120.txt
@@ -0,0 +1,1113 @@
+Stage II, III or IV disease as defined by the Ann Arbor Staging System
+Patients must have Barcelona Clinic Liver Cancer (BCLC) stage: intermediate (B) or advanced (C) within 28 days prior to study entry
+Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites; the following disease groups are eligible:\r\n* Patients with International Neuroblastoma Risk Group (INRG) stage M disease are eligible if found to have either of the following features: \r\n** MYCN amplification (> 4-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features; OR \r\n** Age > 547 days regardless of biologic features\r\n* Patients with INRG stage MS disease with MYCN amplification\r\n* Patients with INRG stage L2 disease with MYCN amplification \r\n* Patients > 547 days of age initially diagnosed with INRG stage L1, L2 or MS disease who progressed to Stage M without prior chemotherapy may enroll within 4 weeks of progression to Stage M\r\n* Patients >= 365 days of age initially diagnosed with MYCN amplified INRG stage L1 disease who progress to Stage M without systemic therapy may enroll within 4 weeks of progression to stage M
+Clinical stage II (T3-4, N-) or stage III (any T, N+) based on magnetic resonance imaging (MRI)
+NYHA classification of III or IV
+Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowed
+Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition
+Completely resected stage IB (>= 4 cm), II or IIIA non-squamous NSCLC with negative margins; patients may not have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
+No other prior malignancy is allowed except for the following:\r\n* Adequately managed stage I or II cancer from which the patient is currently in complete remission\r\n* Any other cancer from which the patient has been disease free for one year\r\n* Adequately managed stage I or II follicular thyroid or prostate cancer is also eligible, wherein patient is not required to be in complete remission
+Patients must have histologically or cytologically confirmed stage IV or unresectable stage III BRAF V600E or BRAF V600K mutant melanoma
+Patients must have unresectable stage III or stage IV disease
+Patients who have received prior chemoradiation for limited-stage SCLC must have been treated with curative intent at least 6 months since last treatment from diagnosis of extensive-stage SCLC
+Patients must have pathologically confirmed melanoma that is either stage IV or unresectable stage III; patients may have primaries of cutaneous, mucosal or unknown origin; patients with uveal (ocular) primary are not eligible
+Stage IV disease (includes M1a, M1b, or recurrent disease), according to the 7th edition of the lung cancer tumor, node, and metastasis (TNM) classification system
+Low risk stratum (stage I ovarian immature teratoma and stage I malignant GCT [all sites]): Patients must be < 50 years of age at enrollment
+Low risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I, Federation of Gynecology and Obstetrics (FIGO) stage IA and IB; grade: 2 or 3; histology: pure immature teratoma, mixed immature and mature teratoma, (no pathological evidence of mediastinal germ cell tumor [MGCT]); tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; age (years) < 50
+Low risk stage I MCGT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA and IB; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); age (years) < 50
+Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC, FIGO stage II-IV; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); age (years) < 11
+Standard risk 2 (SR2)\r\n* Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); age (years) >= 11 and < 25\r\n* Site: testicular; stage: COG stage II-IV, AJCC stage II, III, International Germ Cell Consensus Classification (IGCCC) good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); tumor markers: for IGCCC good risk: alpha-FP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL and lactate dehydrogenase (LDH) < 1.5 x normal; age (years) >= 11 and < 25\r\n* Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed) age (years) >= 11 and < 25
+Patients with any diagnoses not listed including:\r\n* Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection)\r\n* Pure dysgerminoma and pure seminoma\r\n* Pure mature teratoma\r\n* Pure immature teratoma COG stage I with alpha-fetoprotein (AFP) >= 1000 ng/mL\r\n* Pure immature teratoma COG stage II - IV or FIGO stage IC to IV\r\n* Poor risk disease (age >= 11 years old and COG stage IV ovarian, COG stage III or IV EG, or IGCCC intermediate or poor risk testicular), or\r\n* Primary central nervous system (CNS) germ cell tumor
+Stage T2a/b (> 5 cm) and grade 2 or 3 AND
+RMS types included under embryonal rhabdomyosarcoma (ERMS) include those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the 2013 World Health Organization (WHO) classification as ERMS (classic, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant); classification of alveolar rhabdomyosarcoma (ARMS) in the 2013 WHO classification is the same as in the ICR and includes classic and solid variants\r\n* ERMS\r\n** Stage 1, group III (non-orbit)\r\n** Stage 3, group I/II\r\n** Stage 2/3, group III\r\n** Stage 4, group IV, < 10 years old\r\n* ARMS:\r\n** Stages 1-3, groups I-III
+Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition staging criteria
+Patients must have either metastatic (stage IVC) or locally advanced unresectable disease (stage IVB)
+Patients must be:\r\n* < 12 months (< 365 days) of age at diagnosis with INRG stage L1; or\r\n* < 18 months (< 547 days) of age at diagnosis with INRG stage L2 or stage Ms neuroblastoma/ganglioneuroblastoma
+Clinical stage >= T2NxM0 or TanyN+ disease for which radical or partial nephrectomy is planned
+Patients with newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages are eligible:\r\n* Stage IIB with bulk\r\n* Stage IIIB\r\n* Stage IVA\r\n* Stage IVB\r\n** If study eligibility by staging is uncertain, consultation with Imaging and Radiation Oncology Core (IROC) Rhode Island (RI) may be obtained prior to study enrollment
+Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration; this includes patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases.
+Patients must have stage II, III, or IV disease
+Patients with stage I disease are not eligible
+Patients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration; the carcinoma must be stage T1 high-grade, stage CIS, or stage Ta high-grade
+Patients with apparent stage I disease who have not undergone a staging procedure
+Pre- and postmenopausal women or men with Stage II (Stage IIA limited to max. 1000 patients) or Stage III early invasive breast cancer
+Patients with Stage I or IV breast cancer are not eligible.
+Limited-stage patients who are candidates for local or regional therapy
+Subjects who are 12-18 months of age with INSS Stage 4 and all stage 3 subjects with favorable biologic features (ie, nonamplified MYCN, favorable pathology, and DNA index > 1) are not eligible.
+Histologically or cytologically confirmed diagnosis of non-small cell lung carcinoma (NSCLC) who present with stage IIIB/stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resection
+Patients with unresectable or metastatic stage III B/C or IV melanoma. Patients enrolled under this version of the protocol must also have progressed on prior anti-PD-1 therapy, according to RECIST 1.1 criteria. Patients who progressed within 3 months of treatment start are excluded.
+Patients must have histologically confirmed diagnosis of stage IV metastatic melanoma positive for BRAF V600E by a Clinical Laboratory Improvement Amendments (CLIA) approved assay
+Stage III-IV SCCHN and select stage II participants (T2N0 oral cavity cancer with > 5 mm depth invasion)
+Any patient with inflammatory breast cancer or stage IV or confirmed metastatic disease
+Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system
+Subjects must have histologically confirmed metastatic melanoma with measurable (by RECIST v1.1), stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease that is accessible for injection.
+Patients must have histologically confirmed invasive breast cancer with stage IV disease, either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological study
+Curatively treated Stage I uterine cancer
+Clinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 months
+CTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary cells or CD8+ or large cell transformation or Progressive CTCL
+Must have unresectable or inoperable stage IIIA or IIIB disease; subjects must be considered unresectable or inoperable based on the judgment of the treating physician
+Histologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects who are immunotherapy naïve.
+Histologically-confirmed stage IIIb or IV NSCLC by the enrolling institution\r\n* Patients who are highly suspected to have stage IIIb or IV NSCLC and who are planned for a standard-of-care diagnostic biopsy/resection may also be enrolled; patients who are confirmed to have stage IIIb or IV NSCLC will be eligible to continue with screening procedures; those who are found after surgery/biopsy to not have stage IIIb or IV NSCLC will not be eligible continue with screening procedures and may not receive study therapy
+Participants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
+Histologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system
+Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), or next generation sequencing (NGS) via a Clinical Laboratory Improvement Act (CLIA)-certified local diagnostic test (LDT); OR
+Phase 2 Cohorts A & B: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (AJCC stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by FISH, RT-PCR, or NGS via a CLIA-certified LDT
+DCIS or Stage I-III primary invasive carcinoma of the breast
+Ann Arbor stage II-IV disease (Stage I primary mediastinal B-cell lymphoma will also be eligible)
+Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
+Stage B (not applicable for transarterial chemoembolization [TACE]), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
+Patients must have histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx; patients eligible for inclusion must have stage III-IV SCC of the above sites based on current American Joint Committee on Cancer (AJCC) clinical and imaging based staging; only patients with human papillomavirus (HPV)- disease will be included in the phase II portion of the study; HPV status will be ascertained using the currently utilized clinical standard of p16 overexpression via immunohistochemistry
+RANDOMIZED PHASE II CLINICAL TRIAL: Disease stage IV, metastatic unresectable disease
+Stage IV or metastatic breast cancer
+Stage IV melanoma for which surgery is not recommended.
+Patients with confirmed stage IV disease
+Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009).
+Mandatory provision of adequate archived stage IV NSCLC tissue samples or tissue samples other than stage IV NSCLC may be acceptable (optional for part C).
+Unresected operable breast cancer stage II-III with primary tumor > 2.0 cm
+Participants must have histologically or cytologically confirmed stage IV melanoma or recurrent stage IIIc melanoma following primary treatment of surgery and prior treatment or consideration of adjuvant therapy
+Participants must have a clinical indication for resection of metastatic melanoma; patients will be informed about other treatment options for stage IV melanoma including Braf inhibitors and antibodies to CTLA-4
+Patients must be diagnosed with metastatic cytologically or histologically confirmed adenocarcinoma of the breast with HER2 over-expression or with newly diagnosed locally advanced (including inflammatory) breast cancer (LABC) with stage II-III disease; patients with metastatic (stage IV) disease (MBC) must have measurable lesions
+Participants must have histologically confirmed stage IIIA or IIIB non-squamous non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer [AJCC] 7th edition); patients with a clinical stage of IIIB are allowed only if they are thought to be a candidate for concurrent chemoradiation
+Has a histologically confirmed diagnosis of unresectable stage III or metastatic melanoma not amenable to local therapy
+Participants must have histologically confirmed stage IV non-small cell lung cancer (NSCLC) (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act [CLIA]-approved laboratory
+Participants with stage IV-V chronic kidney disease or end stage renal disease
+Has stage III or stage IV disease that is not surgically resectable.
+Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC (American Joint Committee on Cancer version 8)
+Has received prior systemic chemotherapy/other targeted or biological antineoplastic therapy treatment for their Stage IV metastatic NSCLC
+Have histologically- or cytologically-confirmed unresectable stage III or stage IV melanoma not amenable to local therapy
+Stage IV metastatic breast cancer
+Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C
+Participants must have histologically confirmed stage IV NSCLC (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act (CLIA)-approved laboratory
+Participants with stage V chronic kidney disease or end stage renal disease
+American Joint Committee on Cancer (AJCC) (2009) stage IV melanoma, or stage III melanoma not curable by surgery and which is progressing; patients must have at least 1 target lesion measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Has stage III or stage IV disease that is not surgically resectable. Stage IIB (T3N0M0B0-1) cutaneous T cell lymphoma (CTCL) participants are eligible.
+Has stage III or stage IV disease that is not surgically resectable. Stage IIB (T3N0M0B0-1) CTCL participants are eligible.
+Subjects with stage IV non-small cell lung cancer as defined by American Joint Committee on Cancer (AJCC).
+Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease
+Patients with non-metastatic breast cancer are eligible; this includes American Joint Committee on Cancer (AJCC) 7th edition left- or right-sided breast cancer clinical or pathologic stage I, II, III or loco-regionally recurrent at time of diagnosis; for patients that receive neoadjuvant chemotherapy, AJCC 7th edition left- or right-sided breast cancer pathologic stage yp 0, I, II, III are eligible
+Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
+Diagnosed with Stage IV resectable disease
+Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III (excluding visceral or nodal involvement), and must be refractory to or intolerant of established therapies for their condition
+Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC
+Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration\r\n* Radiographic imaging of the chest, abdomen and pelvis within 28 days prior to registration documenting disease consistent with FIGO stage III or IV disease\r\n* Further protocol-specific assessments
+INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLINICAL LABORATORY IMPROVEMENT ACT [CLIA] CERTIFIED LOCATION): Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or non- amplified by FISH) breast cancer that is stage IV
+Histological diagnosis of squamous or non-squamous, inoperable, stage 4 NSCLC
+Histologically confirmed Stage IV (metastatic) or unresectable Stage IIIc (locally advanced) melanoma
+Histologically confirmed unresectable stage III or stage IV melanoma (American Joint Committee on Cancer [AJCC] 7th edition classification); cutaneous melanoma and mucosal melanoma will be eligible
+Patients must have histologically or cytologically confirmed breast cancer with stage IV or unresectable stage III disease
+Must meet criteria for high risk disease\r\n* Patients ? 365 days initially diagnosed with INSS stage 1 or 2 who progressed to a stage 4 without interval chemotherapy
+Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer
+Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer [AJCC] 7th edition) squamous NSCLC.
+Patients must have American Joint Committee on Cancer (AJCC) (2010) clinical stage T3-4, N0-1, M0 disease
+Biopsy-proven, previously untreated stage III or IV squamous cell carcinoma of the larynx, Primary tumor stage (T2, T3) and nodal stage (N0, N1, N2, N3).
+American Joint Committee on Cancer (AJCC) (2009) stage IV cutaneous melanoma or stage III cutaneous or acral melanoma that is judged inoperable; patients with a history of uveal or mucosal melanoma are not eligible
+Histologically-proven diagnosis of advanced (American Joint Committee on Cancer [AJCC], 7th addition: stage III or IV) or aggressive (published disease-specific survival rates less than 20% at 5 years following best currently available therapies) solid organ cancer; this includes but is not limit to: \r\n* Metastatic melanoma\r\n* Esophageal and gastric adenocarcinoma (stage III/IV)\r\n* Cholangiocarcinoma (any stage)\r\n* Pancreatic adenocarcinoma (any stage)\r\n* Gallbladder cancer (any stage)\r\n* Colorectal cancer (stage IV)\r\n* High-grade mucinous appendix cancer (any stage)\r\n* High-grade gastrointestinal neuroendocrine cancer (any stage)\r\n* Mesothelioma (any stage)\r\n* High-grade soft tissue sarcoma (any stage)
+Histologically or cytologically documented Squamous or non-Squamous Non-small cell lung cancer (NSCLC) (Stage IIIB/IV), or recurrent or progressive disease following multimodal therapy
+Any T stage with ? N2 disease;
+T4 disease, any N stage;
+CLL (Part 1): Rai Stage III or IV disease, or stage 0-II disease that meets National Cancer Institute Working Group (NCIWG) criteria for active disease requiring therapy that may include either of the following disease-related symptoms:
+Stage I, II, III, or IV disease; NOTE: stage I disease are eligible only if the disease is not amenable to external beam radiation therapy
+Histologic or cytologic diagnosis of cutaneous melanoma that is considered unresectable (stage III) or metastatic (stage IV); ocular and mucosal melanoma is excluded
+Another previous or current invasive malignancy within the last 2 years, with the exception of curatively treated stage Ia cervical carcinoma, or resected stage Ia endometrial cancer, and noninvasive nonmelanoma skin cancers; patients with gBRCA1/2m and primary breast or ovarian cancers will be eligible for cohort 1
+Patients must have stage III, IVa or IVb disease as determined by imaging studies and complete head and neck exam; staging evaluation should be in accordance with the American Joint Committee on Cancer Staging Manual, 7th edition
+Histologically or cytologically proven Stage IIb-IV melanoma (at diagnosis or at the time of recurrence) rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration; patients with treated brain metastases may be eligible if they meet the criteria. Small radiologic or clinical findings of an indeterminate nature will not be a basis for exclusion, and brain metastases will not be a basis for exclusion.\r\n* Staging of cutaneous melanoma will be based on the 7th edition American Joint Committee on Cancer (AJCC) staging system. Staging of mucosal melanomas will be based on the following system modified from the cutaneous melanoma staging system: 2.01- 4 mm primary with ulceration or > 4 mm primary = stage IIb, lymph node metastases = stage III, distant metastases = stage IV.
+Pathologically proven (either histologic or cytologic) diagnosis of NSCLC with any of the following stages (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition):\r\n* Stage IIIA or IIIB\r\n* Stage II NSCLC with medical contraindication to curative surgical resection\r\n* Stage IV disease with solitary brain metastasis that has been treated radically (eg: with surgical resection or stereotactic radiosurgery) and thoracic disease that would be classified as stage II-III
+Unresectable Stage III or Stage IV melanoma.
+Stage 1, 2, 3 or early and intermediate stage IVa (T1N0-2B, T2N0-2B) (level 2, non-matted) disease without evidence of distant metastases or extracapsular extension; primary site must be lateralized for a functional dissection
+Evidence of distant metastases of stage IV
+Pathologically proven (either histologic or cytologic) diagnosis of stage IIIA or IIIB non-small cell lung cancer; (according to American Joint Committee on Cancer [AJCC] staging, 7th edition) within 4 weeks of registration; the patient should have histologically or cytologically confirmed N2 disease
+Prior exposure to cetuximab in the metastatic (stage IV) setting
+AJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III.
+Clinical stage TIC or T2a
+Must meet stage II - III group criteria per AJCC Staging manual 7th edition.
+Histologically confirmed early stage urothelial carcinoma of the bladder defined as Ta, T1, or Tis stage; tumor staging must be confirmed by TURBT performed within 42 days prior to registration
+Phase I and expansion cohort: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with clinical stage: IV (see American Joint Committee on Cancer [AJCC] staging criteria, 7th edition) or stage IIB-IIIC (expansion cohort only)
+Histological confirmation of ER negative breast carcinoma (defined as less than 10%), stage I, II, or III
+Has evidence of recurrent or metastatic (stage IV) breast cancer
+Lymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade non-Hodgkin lymphoma (NHL) after initial therapy if stage III/IV in first partial response (PR1) or after progression if stage I/II < 1 year; stage III/IV patients are eligible after progression in CR/PR
+All patients must be either stage IIIb/c or stage IV melanoma according to the American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed melanoma that is felt to be surgically unresectable in order to be eligible\r\n* All melanomas, except ocular/uveal melanoma, regardless of primary site of disease will be allowed; mucosal melanomas are eligible\r\n* Patients must not have received prior anticancer treatment for metastatic disease (for example, but not limited to, systemic, local, radiation, radiopharmaceutical)\r\n* Exceptions: Surgery for melanoma and/or post-resection brain radiotherapy (RT) if central nervous system (CNS) metastases and/or prior treatment with adjuvant IFN\r\n* All patients must have their disease status documented by a complete physical examination and imaging studies within 4 weeks prior to the first dose of study drug; imaging studies must include computerized tomography (CT) scan of neck, chest, abdomen, pelvis, and all known sites of resected disease in the setting of stage IIIb/c or stage IV disease, and brain magnetic resonance imaging ([MRI], brain CT allowable if MRI is contraindicated)\r\n* The complete set of baseline radiographic images must be available before treatment initiation
+Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) (8th edition) staging criteria:\r\n* AJCC stage IV (Tany, Nany, M1a(1), M1b(1), M1c(1) or M1d(1))\r\n* AJCC stage IIIC (at least N2b) or IIID with unresectable nodal/locoregional involvement
+Diagnosis of advanced/unresectable melanoma (American Joint Committee on Cancer [AJCC] v.8 stage 3C/D/4)
+Locoregional disease with clinical stage of T1N1 or T2-3N0-2
+Prior endoscopic mucosal resection (EMR) with a diagnosis of stage II or III esophageal cancer is eligible, irrespective of margin status
+Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
+Ann Arbor stage II-IV
+Clinical stage I or II breast cancer for which there will be at least a 2 week period of time between diagnosis and definitive surgery
+History of end-stage renal disease requiring dialysis
+Histological or cytological confirmation diagnosis of stage 4 NSCLC
+Patients with histologically confirmed unresectable stage III or stage IV metastatic melanoma, who have not been previously treated with a SEMA4D antibody and have had prior anti-PD1/PDL1 inhibitors with documented progression; patient may have or not have prior anti-CTLA4 treatments
+Inclusion Criteria Stage 1\n\n          -  ECOG Performance Status of 0 or 1\n\n          -  Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER,\n             and PR expression)\n\n          -  Radiologic/objective evidence of recurrence or disease progression after one line of\n             chemotherapy for metastatic breast cancer MBC\n\n          -  Availability of a representative tumor specimen that is suitable for determination of\n             PD-L1 and/or additional biomarker status via central testing\n\n          -  Eligible for capecitabine monotherapy\n\n          -  Adequate hematologic and end-organ function, laboratory test results, obtained within\n             14 days prior to initiation of study treatment.\n\n          -  Negative HIV test at screening\n\n          -  Negative hepatitis B surface antigen .\n\n          -  Negative hepatitis C virus (HCV) antibody test at screening or positive HCV antibody\n             test followed by a negative HCV RNA test at screening\n\n        Inclusion Criteria for Stage 1 and Stage 2\n\n          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1\n             (RECIST v1.1)\n\n          -  Tumor accessible for biopsy\n\n          -  For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n             during the 14 days prior to initiation of study treatment\n\n          -  For women of childbearing potential: agreement to remain abstinent (refrain from\n             heterosexual intercourse) or use contraceptive measures as outlined for each specific\n             treatment arm\n\n          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use\n             contraceptive measures, and agreement to refrain from donating sperm, as outlined for\n             each specific treatment arm\n\n        Inclusion criteria stage 2\n\n          -  ECOG Performance Status of 0, 1, or 2\n\n          -  Patients randomly allocated to the control arm during Stage 1: ability to initiate\n             Stage 2 treatment within 3 months after experiencing unacceptable toxicity, provided\n             that Medical Monitor approval for entry into Stage 2 is obtained, or disease\n             progression per RECIST v1.1 while receiving control treatment\n\n          -  Patients randomly allocated to an experimental arm during Stage 1: ability to initiate\n             Stage 2 treatment within 3 months after experiencing unacceptable toxicity not related\n             to atezolizumab, disease progression per RECIST v1.1, or loss of clinical benefit as\n             determined by the investigator (see Section 3.1.1.1 for details) while receiving Stage\n             1 treatment\n\n          -  Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage\n             1 (if deemed clinically feasible by the investigator)\n\n        Exclusion Criteria for Stage 1\n\n          -  Prior treatment with any of the protocol-specified study treatments\n\n          -  Treatment with investigational therapy within 28 days prior to initiation of study\n             treatment\n\n          -  Inability to swallow medication or malabsorption condition that would alter the\n             absorption of orally administered medications\n\n          -  Treatment with sorivudine or its chemically related analogues, such as brivudine\n\n          -  History of severe and unexpected reactions to fluoropyrimidine therapy\n\n        Exclusion Criteria for Stage 1 and Stage 2\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures (once monthly or more frequently)\n\n          -  Uncontrolled tumor-related pain\n\n          -  Symptomatic, untreated, or actively progressing CNS metastases\n\n          -  History of leptomeningeal disease\n\n          -  Active or history of autoimmune disease or immune deficiency\n\n          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis\n             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of\n             active pneumonitis on screening chest computed tomography (CT) scan History of\n             radiation pneumonitis in the radiation field (fibrosis) is permitted.\n\n          -  Active tuberculosis\n\n          -  Severe infection within 4 weeks prior to initiation of study treatment\n\n          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation\n             of study treatment\n\n          -  Significant cardiovascular disease\n\n          -  Prior allogeneic stem cell or solid organ transplantation\n\n          -  History of malignancy other than breast cancer within 2 years prior to screening, with\n             the exception of those with a negligible risk of metastasis or death\n\n          -  Treatment with systemic immunosuppressive medication (including, but not limited to,\n             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and\n             anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study\n             treatment, or anticipation of need for systemic immunosuppressive medication during\n             the course of the study\n\n          -  Pregnancy or breastfeeding, or intention of becoming pregnant during the study
+Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated, with principal investigator (PI) confirmation; carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) 2009 stage I and stage II, with one of the following combinations of stage and grade:\r\n* Stage IA, grade 2, 3\r\n* Stage IB, grades 1-3\r\n* Stage II, grades 1-3
+Clinical or pathologic stage T2 –T4 disease including T4a and 4b if feasible to treat with radiation therapy
+Cervical carcinoma Stage 1B or less
+Confirmed diagnosis of Stage III or Stage IV NSCLC and have received ? 1 line of prior systemic therapy in the locally advanced or metastatic setting
+Stage IIIB/IV or recurrent non-small cell lung cancer which is not amenable to curative intent therapy
+Patients with advanced stage non-mycosis fungoides (MF) CTCL are eligible including, but not limited to, advanced stage lymphomatoid papulosis (LyP) or primary cutaneous anaplastic large cell lymphoma (pcALCL)
+Patients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible.
+STUDY ENTRY: No prior treatment for primary advanced (stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
+Stage IV (according to the American Joint Committee on Cancer [AJCC] 8th edition).
+Stage IV disease (metastatic or surgically unresectable, cT4b, N+, or M+ cancer)
+NYHA classification of III or IV
+Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA.
+Clinical stage T2-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging
+Has FIGO Stage IVB
+Eligible tumors must meet one of the following criteria: Stage II or III, or T4, any N, M0, including clinical or pathologic inflammatory cancer or Regional Stage IV, where supraclavicular lymph nodes are the only sites metastasis
+Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma
+Patients must have recurrent or metastatic HNSCC stage III/IV that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
+Stage I-IIIA (stage I tumors must be >= 4 cm)
+Final American Joint Committee on Cancer (AJCC) version 7.0 stage 0-IIB (pathologic stage Tis, T1-T3, all must be N0 and M0 status)
+Patients who have stage III-IV disease without distant metastases (M0) of 1) oral cavity, 2) larynx, 3) hypopharynx 4) oropharynx (human papillomavirus [HPV] negative [neg]) using American Joint Committee on Cancer (AJCC) 8th edition
+Patients who have oropharyngeal cancer that is HPV positive, stage II-III disease without distant metastases (M0) using AJCC 8th edition
+Have a histologically or cytologically confirmed diagnosis of unresectable stage III or IV melanoma; patient may not have a diagnosis of uveal or mucosal melanoma
+Histologically or cytologically confirmed diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to curative local therapy
+Patients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, stage IIIB – IIIC with optimal (=< 1 cm) residual disease
+Have unresectable (stage III) or advanced (stage IV) melanoma
+Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition proposed staging criteria
+Patients with stage I-IVA are eligible
+The following tumor stage and Gleason scores: a) clinical >= stage T1c/T2 tumor with Gleason score >=8 b) clinical stage >= T2b tumor with Gleason score >= 7 and PSA > 10 ng/ml.
+Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization [WHO] type 2a and 2b non-keratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registration
+Patients must have stage IIIB, IIIC, or IVM1a (equivalent staging at time of enrollment) metastatic melanoma which is eligible for complete surgical resection
+Have unresectable stage III or stage IV melanoma
+Clinical stage T1-2, N0-1, or small volume N2b (American Joint Committee on Cancer [AJCC], 7th ed.), with no distant metastases, based on routine staging workup.
+Have a histologic diagnosis of stage IV NSCLC
+Clinical stage T1-T2, N1-N2b or T3, N1-N2b (American Joint Committee on Cancer [AJCC] 7th edition) with no distant metastases based on the following diagnostic workup
+Stage 4 cancer
+Eligibility for stage 2 of the study, if the extension stage is opened, will be determined by ribonucleic acid sequencing (RNAseq) analysis and master regulator profile of a single fresh needle biopsy specimen obtained during study screening
+Clinical stage T1c-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging prior to neoadjuvant chemotherapy
+Patients must have stage II-IV disease
+Inoperable per local Investigator (Masaoka stage III or IV)
+Histologically or cytologically confirmed malignant melanoma at Screeningthat is unresectable/unresected Stage IIIB, IIIC, IIID or IV. Patients with unresectable mucosal melanoma may be enrolled after consultation with the Medical Monitor.
+Patients must have received and failed or refused available therapy for unresectable/unresected Stage III or IV melanoma.
+High-risk NB as defined as any of the following: \r\n* Stage 4 with MYCN amplification (any age)\r\n* Stage 4 without MYCN amplification (> 1.5 years of age)\r\n* Stage 3 with MYCN amplification (unresectable; any age)\r\n* Stage 4S with MYCN amplification (any age)
+Female subjects with CA125-associated, advanced ovarian cancer (FIGO Stage III/IV) previously treated and now presenting with recurrent or persistent disease.
+Histologically proven stage IV non-small cell lung cancer
+Stage IA, IB, IIA, IIB, or IIIA (according to AJCC 7th edition). Patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor
+History of another cancer within 3 years before enrollment with the exception of nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor.
+Clinical stage I (breast tumor >= 1.0 cm in diameter), stage II or stage III breast cancer (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th Edition, 2010); multifocal disease is allowed if confined to 1 breast, as long as one tumor is at least 1 cm and meets all of the other inclusion criteria
+Unresectable stage II, IIIA, or IIIB disease
+Stage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria.
+There is no requirement nor restriction for prior therapy or stage
+Stage I or selected stage IIa according to the 7th version of the International Association for the Study of Lung Cancer (IASLC) system: stage I (T1 or T2a [tumor size =< 5 cm] N0M0) stage IIa (T2 [tumor size > 5 cm but =< 7 cm] N0M0)
+Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] version 7.0 Staging manual) NSCLC
+Histologically confirmed clinical or pathological stage 2 through stage 3c primary adenocarcinoma of the breast
+Stage IA-IIIA NSCLC by 8th edition American Joint Committee on Cancer (AJCC) staging (that is deemed to be surgically resectable by a board certified thoracic surgeon
+Stage IIIB or IV NSCLC as per 8th edition AJCC staging
+Patients must have histologically or cytological confirmed stage IIIB or IV non-small cell lung cancer
+Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (Stage IV) and not amenable to resection with curative intent.
+Histological or cytological evidence of stage IV non-small cell lung cancer (NSCLC) (any histology)
+All subjects must be either recurrent or stage IV American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed Merkel cell carcinoma with confirmed pathology in order to be eligible
+Clinical stage I-IVB (American Joint Committee on Cancer [AJCC], 7th edition); stages I-II glottic cancer are excluded
+Stage I and II glottic carcinoma
+Metastatic (American Joint Committee on Cancer [AJCC] stage IV) RCC
+Disease eligibility and stage\r\n* Histologically confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or renal carcinoma\r\n* Previously treated or previously untreated stage IV melanoma, stage IV lung cancer, and metastatic renal cancer by American Joint Committee on Cancer (AJCC) staging criteria\r\n* Presence of a lesion that is suitable for hypofractionated radiotherapy
+Patients must have histologically confirmed, locally advanced or metastatic stage IV or non-resectable stage III non-small cell lung cancer (NSCLC)
+Patients must have high-risk NB (MYCN-amplified stage 2/3/4/4S of any age and MYCN-nonamplified stage 4 in patients greater than 18 months of age)
+Recurrent or persistent histologically proven locoregional OCSCC (recurrent T-stage 2-4) that was initially treated with surgery alone; to allow sufficient tumor tissue for the immunological analyses, patients with T-stage 1 OCSCC will be excluded
+Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
+Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
+Failure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
+Patients must have stage I to III histologically confirmed invasive carcinoma of the breast; a minimum tumor size of at least 1.5 cm determined by physical exam or imaging (whichever is larger) is required
+NYHA classification of III or IV
+Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; Phase 2: >= stage IB\r\n* Stage of disease according to TNMB classification\r\n* Pathology report must be diagnostic or be consistent with MF/SS criteria\r\n* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\r\n* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used
+Clinical or pathologic stage Stage III-IVb per the American Joint Committee on Cancer (AJCC), 7th edition.
+Stage I or II; T1N1 and T2N1 stage III presentations per AJCC 7th edition
+Subjects who are ipilimumab naive with progressive unresectable stage III or stage IV melanoma; eligible patients may have had prior adjuvant therapy, but not including ipilimumab, and been treated with up to 3 prior treatments for metastatic melanoma (eg, chemotherapy, other biologic or targeted therapy or IL-2)
+Histologic or cytologic confirmation of stage III or stage IV melanoma
+Stage at least T2 or greater
+Have pathologically confirmed diagnosis of advanced NSCLC (stage IIIB or stage IV, as defined by the American Joint Committee on Cancer staging system-TNM 7th edition, 2010)
+Presumed American Joint Committee on Cancer (AJCC) tumor stage I or II
+AJCC stage III/IV differentiated thyroid cancer
+Stage 3 or 4 disease without evidence of distant metastases
+Pathologically confirmed unicentric invasive breast cancer defined as radiologic clinical stage T1 or T2 (=< 5 cm), N0 or N1 (=< 4 abnormal axillary nodes on initial ultrasound), clinical stage M0
+Have Barcelona Clinic Liver Cancer (BCLC) stage C disease or BCLC stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach
+Must have clinically node negative stage I (T1N0) or stage II (T2N0) breast cancer\r\n* Preoperative ultrasound of the axilla with biopsy of suspicious nodes is recommended as clinically indicated per the discretion of the treating physician
+Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] staging manual) NSCLC
+Histologically confirmed metastatic melanoma (stage IV) or unresectable stage III; patients with BRAF or BRAF-wild-type are eligible; only BRAF V600 mutated melanoma will be eligible for the triplet arm while BRAF-wild-type or NRAS-mutated melanoma will be eligible for the doublet arm
+Histological or cytological confirmation of colorectal cancer (CRC) with available tissue, currently stage IV
+Histologically confirmed stage III-IV high-grade epithelial non-mucinous ovarian, fallopian tube, or primary peritoneal cancers
+Patients must have histologically or cytologically confirmed stage IIIB or IV (American Joint Committee on Cancer, 7th edition; AJCC 7) non-small cell lung cancer
+Histologically diagnosed or cytologically proven advanced or metastatic NSCLC patients, either Stage IIIB/Stage IV disease (according to Version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resection;
+Subjects must have histologically or cytologically-documented stage IIIB or stage IV, recurrent, or metastatic non-small cell lung cancer (NSCLC)
+American Joint Committee on Cancer (AJCC) stage 3 or 4 histologically proven NSCLC not amenable to curative therapy
+Clinical stage IV cancer
+Clinical stage IB (>= 3 cm per computed tomography [CT]), stage IIA/IIB, or stage IIIA (N0-2) amenable to surgical resection
+Patients who have unresectable stage III through stage IV metastatic melanoma that have not received prior PD-1 directed therapy (Arm A) or that have progressed despite prior PD-1 directed therapy (Arm B)
+a diagnosis of stage I, II, or III breast cancer;
+Stage 0 or Stage IV BC
+Patients with T stage T1-3
+Patients with N stage N0-N2c
+Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7) non-small cell lung cancer
+Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria:\r\n* AJCC stage IV (T any, N any, M1a, b, or c)\r\n* AJCC stage IIIB or IIIC with unresectable nodal/locoregional involvement
+Patients must have stage IV melanoma, with newly identified brain or spine metastases
+American Joint Committee on Cancer (AJCC) clinical stage T2-T3 N0M0
+Is on anticoagulation that cannot be discontinued in the perioperative stage
+Measurable, unresectable stage III (in transit lesions) or stage IVA, IVB or IVC disease
+Has clinical stage T2-T4a N0/X M0 urothelial carcinoma; clinical T stage is based on the pre-study standard of care transurethral resection of the bladder tumor (TURBT) sample and imaging studies
+Patient's disease state must be American Joint Committee on Cancer (AJCC) 7th edition stage I-III
+Appropriate staging studies identifying as American Joint Committee on Cancer (AJCC) stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less
+T2 (> 3.0 cm), T3, stage III, or stage IV breast cancer
+Lymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year
+other adequately treated Stage 1 or 2 cancer currently in complete remission;
+Histologically or cytologically proven diagnosis of NSCLC that is locally advanced (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the 7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International Union Against Cancer and the American Joint Committee on Cancer.
+High-risk NB as defined by risk-related treatment guidelines' and the International NB Staging System, i.e., stage 4 with (any age) or without (> 365 days of age) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), or MYCN-amplified stage 4S
+Have a histologic or cytologic diagnosis of stage IV NSCLC
+Radiographically confirmed endometrial adenocarcinoma of stages III-IV requiring adjuvant therapy; if stage III disease is suspected, there should be multiple pelvic and/and or lymph nodes involved
+Radiographic imaging demonstrating uterine cancer that is probably stage I or II
+Patients with MF/SS must have stage IB, IIA, IIB, III or IV disease; patients with primary cutaneous CD30-positive lymphoproliferative disorder must have multifocal symptomatic or extensive lesions requiring systemic treatment
+Participants with age greater than or equal to (>=) 18 years with either unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF
+Diagnosed with stage III colon or stage II/III rectal cancer that will receive neoadjuvant or adjuvant chemotherapy but have not yet started
+Colon cancer stages I-II and IV or rectal cancer stage I or IV
+Patients with a history of stage IV or metastatic disease
+Stage III or stage IV metastatic melanoma as defined on imaging studies performed within 28 days of first dose of pembrolizumab and clinical exam performed within 14 days of first dose of pembrolizumab
+CAPMATINIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
+CERITINIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
+REGORAFENIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
+ENTRECTINIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteria
+Have TNM clinical stage III, IVA, or IVB disease
+Patients with TNM Stage IVC disease
+Biopsy proven HNSCC of the oropharynx, larynx, hypopharynx, or oral cavity stage III-IVB as defined by American Joint Committee on Cancer (AJCC) T0 - T4, N0 - N3, M0
+Biopsy-confirmed CD4+ mycosis fungoides or Sézary syndrome, stage IB to IIIB
+Patients must have pathologic diagnosis of adenocarcinoma or large cell carcinoma of the lung with confirmation by immunohistochemistry (e.g., transcription termination factor 1 [TTF-1] positivity) (histologic tissue diagnosis is recommended, but cytology is acceptable); stage IIIA/IIIB or oligometastatic stage IV in which the patient is still considered an appropriate candidate for aggressive chemoradiotherapy for the primary tumor; oligometastatic disease is defined as =< 5 metastatic sites (=< 3 lesions per organ); for intracranial metastasis, the patient should have asymptomatic disease that is stable on steroids or 1 to 3 symptomatic metastatic lesions treated with stereotactic radiosurgery (SRS)
+Baseline clinical stage of T1N0 or inoperable T4 (unequivocal organ involvement) are to be excluded
+Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.
+Stage IIIB or IV NSCLC (any histology) at the time of study entry
+Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC.
+Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent
+AJCC stage III or IV completely resectable melanoma identified before surgery
+Must not have had prior systemic therapy for stage IV RCC (except for nivolumab as part of part A of this protocol)
+Stage IIIB-IV, locally advanced or metastatic disease according to the 7 th edition of the AJCC lung cancer TNM classification system
+Patients with FIGO 2009 Stage IVB endometrial cancer.
+Patients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal disease
+Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer (NSCLC) (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
+Insufficient breast imaging to judge clinical stage
+Insufficient breast imaging to judge clinical stage
+Clinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease
+Clinical stage N0, M0
+Clinical stage IV invasive mammary carcinoma
+Medically unresectable (stage I-II) or locally advanced (stage III); patients with distant metastases (stage IV) must have stable disease or improved disease (partial response, or complete response) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined on serial imaging following a course of chemotherapy
+Stage IV metastatic disease (only during the phase II)
+The subject must have clinical stage III or resectable stage IV MEL; subject’s may not have a diagnosis of uveal or mucosal melanoma
+Patients must have histologically confirmed stage IV non-squamous histology non-small cell lung cancer
+Has stage IV or recurrent disease that has been treated
+Histologic diagnosis of either limited stage SCLC (LS-SCLC), or extensive stage SCLC (ES-SCLC) or neuroendocrine tumor
+Individuals with stage IIIB or IV, unresectable non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for stage IIIB or IV disease, and who are not candidates for curative surgery or radiation therapy
+For cohort 1: early stage MF (low or intermediate 1 stage as defined by Dynamic International Prognostic Scoring System [DIPSS]) without currently available treatment options
+Advanced stage non-small cell lung cancer (NSCLC)
+End-stage renal disease (i.e., any patient requiring or advised to undergo dialysis)
+Documented history of clinical stage IV (any T, any N, M1a/b) disease as per American Joint Committee on Cancer (AJCC) staging system 7th edition
+Stage IV cancer by American Joint Committee on Cancer (AJCC) staging criteria (except for pancreatic cancer cohort)
+Stage IV non-small cell lung cancer or recurrent disease which cannot be approached with curative intent
+Patients must be classified post-operatively as Stage IB (? 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).
+Clinical American Joint Committee on Cancer (AJCC) stage (7th edition) IIA-IIIB NSCLC (T1-4N0-3M0)
+Stage - NSCLC with primary resection option for potential cure, as assessed by a faculty surgeon at SKCCC or MSKCC; this may include clinical stage IB (>= 4 cm), II and IIIA; subjects with N3 nodal involvement are not included
+Patients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIIC
+T-2 (> 3.0 cm), T-3, stage III, or stage IV breast cancer
+Clinical stage a =< T1-2a (American Joint Committee on Cancer [AJCC] 7th edition)
+Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have:\r\n* No evidence of disease (NED), or \r\n* Stable bone only disease
+Histological/cytologically documented primary International Federation of Gynecology and Obstetrics (FIGO) stage 3C1, 3C2, stage 4A, and 4B uterine serous carcinoma; in addition, certain stage 3A and B disease are also allowed\r\n* Residual disease after primary surgery:\r\n** Eligible:\r\n*** Stage 3A and B (pelvic, but confined to adnexa or vagina), residual disease present\r\n*** Stage 3CI (pelvic node positive)\r\n*** Stage 3CII (para-aortic node positive)\r\n*** Stage 4A (bladder or pelvic bowel)\r\n*** Stage 4B (distant metastases [mets] including abdominal mets), completely resected\r\n** Not eligible\r\n*** Stage 3A and B (pelvic, but confined to adnexa or vagina), completely resected\r\n*** Stage 4B (distant mets including abdominal mets), residual disease present
+Patient must have a histologically or cytologically confirmed diagnosis of unresectable stage III or IV melanoma; patient may not have a diagnosis of uveal melanoma
+Pathologically confirmed stage pT1-T3, pN0, M0 disease
+Histological/cytological diagnosis of melanoma. AJCC stage IV (any T, any N, M1), metastatic, progressive, refractory, melanoma.
+Patients may have advanced unresectable stage IV disease, resectable stave IV disease or recently resected stage IV disease (<10 weeks prior) with no apparent disease.
+Pathologically proven (either histologic or cytologic) diagnosis of stage IV or recurrent non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
+Ann Arbor stage I - stage IV DLBCL at the time of relapsed/refractory disease to be eligible
+Patients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal disease (Turnstile I)
+Diagnosed with stage I-IV breast cancer
+Patients must have histologically confirmed adenocarcinoma of the breast associated with the following clinical stage: IIA, IIB, IIIA, IIIB, or IIIC; patients with stage IV disease are also eligible if there is an intention to perform breast surgery after neoadjuvant therapy is completed, or in patients participating in clinical trials where surgery after neoadjuvant therapy may be an option (eg. E2108)
+Histologically confirmed stage III colorectal cancer as determined by American Joint Committee on Cancer (AJCC) 7th edition
+Eligible patients will have a histologic or cytologic diagnosis of NSCLC of the advanced stage (IV), with no known curative treatment options
+American Joint Committee on Cancer (AJCC) T1 or T2; N0 or N1microscopic (mic); stage IA-IIA breast cancer
+Patients with stage IB or II cutaneous melanoma
+Patients must have documented, clinically measurable 7th edition American Joint Committee on Cancer (AJCC) stage IIIB/C (bulky nodal and/or in transit disease) or stage IV (distant metastatic) melanoma; patients with brain metastases that have been appropriately treated with surgical resection and/or radiation are eligible for inclusion if they meet the performance status and life expectancy criteria; patients who are BRAF V600E mutation positive need to have failed, refused, or be ineligible for at least 2 lines of therapy (vemurafenib plus one other regimen)
+A history of AJCC stage IIIB/C or stage IV melanoma but no current clinical evidence of metastatic disease
+Patients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal disease (Turnstile I)
+Stage IV or locally advanced cancers for which no alternative therapies with proven survival advantage are available
+Stage IV (American Joint Committee on Cancer [AJCC]) breast cancer patients who have failed at least one conventional therapy for metastatic disease
+Disease must be stage III or IV
+Patient must have a medical oncology consult and be recommended to receive or are currently receiving neoadjuvant chemotherapy for a stage IIB through IV carcinoma
+FIGO 2008 stage 1B2, 2B, 3B, 4A
+FIGO stage 3A disease
+Prior endoscopic mucosal resection (EMR) with a diagnosis of stage II-III esophageal cancer is eligible
+Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American Association for the Study of Liver Disease [AASLD] guidelines)
+Patients with advanced melanoma defined as unresectable stage III or metastatic stage IV disease. Patients with acral or mucosal melanoma or patients with unknown primary melanoma are acceptable in Phase 1b but are excluded from Phase II. Patients with uveal melanoma are excluded from the study.
+Cervical carcinoma stage 1B or less
+Ann Arbor stage I or II disease
+Patients must have a pathologically confirmed diagnosis, either at MSKCC or at the participating site, of stage I-III malignant pleural mesothelioma
+Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0-1 being eligible; and have a primary tumor of the pancreas (i.e., pancreatic head, neck, uncinate process, body/tail
+The patient must have stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less
+T2 (> 3.0 cm), T3, stage III, or stage IV breast cancer
+Have a history of surgically resected and pathologically proved American Joint Committee on Cancer (AJCC) stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreas
+Stage IIIA or Potentially resectable superior sulcus tumors
+Histologically-documented high-risk endometrioid adenocarcinoma with no visible residual disease, defined by the following criteria:\r\n* Surgical stage I disease with < 50 myometrial invasion and grade 3 tumor (IAG3) with lymphovascular space involvement;\r\n* Surgical stage I disease with >= 50% myometrial invasion and grade 2 or 3 tumor (IBG2, IBG3);\r\n* Any surgical stage II disease (II);\r\n* Any surgical stage III disease (IIIA, IIIB, IIIC); and\r\n* Any surgical stage IV disease with no residual macroscopic tumor
+Clinical stage T1b-T2b, N0-Nx, M0-Mx (American Joint Committee on Cancer [AJCC] 6th Edition)\r\n* T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, computed tomography [CT], and/or magnetic resonance imaging [MRI])\r\n* M-stage determined by physical exam, CT or MRI; bone scan not required unless clinical findings suggest possible osseous metastases
+Patients must have measurable or evaluable Stage IV breast cancer
+High-risk NB as defined by risk-related treatment guidelines and the International NB Staging System, i.e., stage 4 with (any age) or without (> 18 months old) myelocytomatosis viral related oncogene (MYCN) amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapy
+Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease (Turnstile I)
+Lymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year
+Patients with any stage of disease will be eligible
+Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
+Stage IV disease
+Have histologically proven diagnosis of: non-small cell lung cancer (NSCLC) (stage I, II, or IIIa)
+Stage IIIb
+Lymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year
+Patients who have received previous treatment for metastatic or stage IV disease
+Patients with biopsy-proven adenocarcinoma, stage II- IV rectal cancer.
+Patients must be candidates for planned surgical resection of their primary rectal cancer 8 - 12 weeks after completion of neoadjuvant chemoRT, even if stage IV.
+Diagnosis of Federation of Gynecology and Obstetrics (FIGO) stage III or grade IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, has received at least 3 cycles of first line intravenous (IV)/IP cisplatin and paclitaxel chemotherapy and has stable disease or better as defined by measurable/evaluable tumor and/or CA-125 levels
+Mayo stage II or IIIa
+Inclusion Criteria:\n\n        Each participant must meet all the following inclusion criteria to be enrolled in the\n        study:\n\n          1. Histologically confirmed CD30+ classical HL.\n\n          2. Advanced stage, newly diagnosed HL (Stage III and Stage IV disease).\n\n          3. Treatment-naive HL.\n\n          4. Have performance scores of greater than or equal to (>=) 50 for Lansky\n             Play-performance or Karnofsky Performance Status.\n\n        Exclusion Criteria:\n\n          1. Nodular lymphocyte predominant HL.\n\n          2. Known active cerebral/meningeal disease, including signs or symptoms of progressive\n             multifocal leukoencephalopathy (PML) or any history of PML.\n\n          3. Any sensory or motor peripheral neuropathy.\n\n          4. Symptomatic neurologic disease compromising normal activities of daily living or\n             requiring medications.
+New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
+Histologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can be safely irradiated in the opinion of the radiation oncologist (note: subjects with primary ocular and mucosal melanoma are permitted). Lesions may include, but are not limited to:
+Ann Arbor Stage II, III or IV
+Patients must have a histologically or cytologically confirmed, unresectable, advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC
+Stage IV (metastatic) disease.
+Participants must have histologically confirmed unresectable stage III or stage IV melanoma
+Treatment of unresectable stage III or stage IV melanoma with a tyrosine kinase inhibitor within prior 4 months; sorafenib for purposes of eligibility will not be considered acceptable prior therapy
+More than 3 prior systemic therapies for unresectable stage III or stage IV melanoma
+Patient with histologically or cytologically confirmed non-resectable or metastatic stage 3 (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage 4 melanoma
+Stage IV disease
+Significant medical disease other than Stage IV breast cancer
+Stage 3 or 4 disease without evidence of distant metastases
+Stage I-III (according to ENSAT classification 2008; see Appendix 2)
+Scheduled to undergo immediate, post-mastectomy, tissue assisted breast reconstruction, Reconstruction shall be either one-stage (direct-to-implant) or two-stage, unilateral or bilateral, prophylactic or therapeutic
+Subjects must have either stage IV breast or ovarian cancer in remission or with stable disease on trastuzumab monotherapy
+Stage IV pathologically proven NSCLC.
+Has a histologically- or cytologically-confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for advanced disease
+Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or stage IV disease, who received no prior systemic treatment for recurrent or metastatic NSCLC
+Stage IV breast cancer
+Patient with disease (stage) eligible per cohort
+Rai stage 0 - II without active disease according to IWCLL 2008 criteria
+Stage IV (metastatic) disease
+Histologically confirmed cutaneous T-cell non-Hodgkin lymphoma (CTCL) per World Health Organization (WHO) classification 2016 including, mycosis fungoides (MF) or Sezary syndrome (SS); phase 1 : >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; expansion cohort: >= stage IB\r\n* MF/SS stage of disease according to TNMB classification\r\n* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\r\n* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society for Cutaneous Lymphomas (ISCL) should be used
+Patients must be appropriate candidates for at least 2 cycles of ABVD or AVD (this could include patients ranging from favorable risk early stage disease to poor prognosis advanced stage disease)
+Stage IV or metastatic/recurrent non-small cell lung cancer; for expansion cohorts, patient’s tumor must also harbor a KRAS mutation detected in a CLIA certified laboratory
+Clinical stage II or stage III (by American Joint Committee on Cancer [AJCC] 7th edition) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal
+Tis-T3 Urothelial cancer; patients will be stratified according to clinical stage
+Pathological stage I-IVa HNSCC
+Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer [AJCC] criteria) not amenable to local therapy
+Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
+Cervical carcinoma of Stage 1B or less.
+Histologically confirmed locally advanced unresectable (stage III) or stage IV pancreatic ductal adenocarcinoma (PDAC)
+Intermediate-risk group: Oropharynx cancer that is p16-positive by immunohistochemistry with smoking status > 10 Pack-years, stage T1-2N2b-N3 OR ? 10 pack-years, stage T4N0-N3 or T1-3N3.
+Patients must have unresectable stage III or stage IV melanoma; patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive
+Diagnosis of stage IV melanoma
+Participants must have presented at initial diagnosis with extensive-stage disease (defined as stage IV [T any, N any, M1a/b] per National Comprehensive Cancer Network [NCCN] guidelines version 1.2015, American Joint committee on Cancer [AJCC] staging manual, seventh [7th] edition, 2010)
+Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC); patients should have stage IV disease (American Joint Committee on Cancer [AJCC] 7th edition), stage IIIb disease that is not amenable to potentially curative treatment (e.g. chemoradiotherapy) or unequivocal progression in a prior irradiated field; measurable or evaluable disease is required
+Subjects must have one of the following risk factors:\r\n* Prostate-specific antigen (PSA) >= 20 and/or\r\n* Gleason score >= 8 and/or\r\n* Clinical or radiographic stage >= T3a per American Joint Committee on Cancer (AJCC) 7th Edition Staging Manual and/or\r\n* Radiographic pelvic lymph node positive disease and/or\r\n* At least two out of four of the following: PSA 10-19.9, Gleason score (GS) = 3+4, clinical stage = T2b/T2c, >= 50% positive biopsy cores
+FOR PATIENTS IN STAGE 1 (PATIENTS #1-#17)
+FOR PATIENTS IN STAGE 2 (ENROLLED PATIENT #18 AND BEYOND)
+STAGE I
+Pathologic diagnosis of stage IB2-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous or adenocarcinoma of the vulva that is not amenable to curative surgical resection alone
+Stage IV disease
+Visceral aGVHD defined as: at least stage III/IV acute liver or stage II/III gastrointestinal (GI) GVHD by clinical criteria and/or GI and/or liver biopsy confirmation showing no alternative explanation for symptoms of GVHD
+Patients must have American Joint Committee on Cancer (AJCC) stage IIIC unresected or IV disease
+Stage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic)
+Melanoma cohort only: histologic proof of surgically unresectable stage IV malignant melanoma
+Pathologically confirmed, clinically evident (by physical examination or radiographic imaging) stage IIIB, IIIC, and IV M1a and b cutaneous melanoma (anatomic stages T1-4b N1a and T1-4b N2a not included); the current diagnosis may be the patient’s first diagnosis of melanoma or recurrent melanoma after previous diagnosis of an earlier stage melanoma
+All subjects must have one of the following stages: stage IA (T1NO); IB (T2NO), II & IIIA (N2 negative); IIIA (N2+), IIIB (N3+)
+Participants who have been diagnosed with clinical or pathologic stage IB to stage IIIA adenocarcinoma of the breast (any subtype) who have undergone, and recovered from primary therapy (any combination of surgery, radiation, and/or chemotherapy and/or trastuzumab used to treat newly diagnosed disease), with their last dose/treatment (of any single or combination treatment) being between 45 days and 6 months (180 days) prior to enrollment; staging will be based on the Seventh Edition American Joint Committee on Cancer (AJCC) staging system; (systemic staging with computed tomography [CT] or positron emission tomography [PET] scans is not required by AJCC and is not required nor exclusionary for this trial)
+Patients must have Durie-Salmon stage II or III disease
+Patients with histologically proven stage III or IV ovarian, fallopian tube or primary peritoneal serous carcinoma (or patients of any stage with recurrent disease) who demonstrate lack of disease progression as determined by clinical assessment as well as cancer antigen 125 (CA-125) levels and/or radiographic assessment
+American Joint Committee on Cancer (AJCC) clinical stage I with T1 > 1.5 cm, stage II or III invasive breast cancer; participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study and no tumor is HER2-positive; in this circumstance, the investigator must determine which will represent the target lesion to be assessed for response; this should remain consistent throughout the study; the target lesion should be selected on the basis of its size (lesion with the longest diameter) and suitability for accurate repetitive measurements
+Histologic or cytologic diagnosis of cutaneous melanoma, mucosal melanoma, or melanoma of unknown primary that is considered unresectable (stage III) or metastatic (stage IV)
+Chronic kidney disease > stage 3.
+T stage of T2 with the tumor > 3 cm in maximum diameter or a T stage >= 3
+Patients must have primary cutaneous melanoma that belong to one of the following American Joint Commission on Cancer (AJCC) stages (2009 AJCC Melanoma Staging System):\r\n* Stage IIIB\r\n** T1-4b N1a M0\r\n** T1-4b N2a M0\r\n** T1-4b N1b M0\r\n** T1-4b N2b M0\r\n** T1-4b N2c M0\r\n* Stage IIIC\r\n** T1-4b N1b M0\r\n** T1-4b N2b M0\r\n** T1-4b N2c M0\r\n** Any T N3 M0\r\n* Stage IV \r\n** M1a\r\n** M1b\r\n** NOTE: patients with stage IV melanoma must have normal lactate dehydrogenase (LDH) and either distant skin, subcutaneous, lymph node, or lung metastases, but no other visceral metastases in order to be eligible; for patients with resected stage IV melanoma, LDH within the institutional upper limit of normal (ULN) must be documented within 4 weeks prior to randomization
+Patients with stage IV (locally advanced or metastatic) disease; the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition will be used for staging; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria will be used for measurable disease
+Patients with newly diagnosed, histologically confirmed Hodgkin lymphoma (HD) who meet the following criteria:\r\n* Stage IA and IB (excluding non-bulky nodular lymphocyte predominant)\r\n* Stage IIA and IIB\r\n* Stage IIIA\r\n* Stage IVA
+Patients with stage IIIB (not eligible for definitive chemo-radiotherapy), stage IV, or recurrent non-small cell lung cancer (NSCLC); patients with stage IV NSCLC should have previously received platinum based doublet chemotherapy; patients with a new diagnosis of stage IV NSCLC are eligible if they have an initial requirement for palliative (radiation therapy) XRT for symptomatic lesion (example: painful bone lesion or obstructive airway)
+HER-2 negative breast cancer that at the time of study entry is either stage III (locally advanced) disease not amenable to curative therapy or stage IV disease; histological confirmation of recurrent/metastatic disease is encouraged but not required if clinical evidence of stage IV disease is available
+Breast cancer patients with stage 0, stage I, stage IIA
+Stage 2 endometrial and ovarian cancer patients must have at least one lesion amenable to biopsy; this determination will be made by a member of the interventional radiology team or surgical associate investigator and an associate investigator; this requirement is not necessary for patients in stage 1
+Clinical stage III or IV
+Patients who have had prior systemic therapy or radiotherapy for stage III or IV epithelial ovarian, fallopian or primary peritoneal carcinoma
+Pathologically or cytologically documented stage IIIB/IV non-small cell lung cancer, or unresectable recurrent disease following locoregional treatment
+Patients must have histological or cytological confirmed melanoma that is metastatic or that is unresectable stage III and clearly progressive
+Have histologically proven diagnosis of non-small cell lung cancer (NSCLC) (stage III and stage IV [to include limited volume metastases such as brain, bone, adrenal])
+Histologically confirmed infiltrating carcinoma of the breast (stage I-III)
+Stage III or stage IVA or IVB disease prior to induction chemotherapy with no proven hematogenous metastatic disease
+Patients with metastatic disease (only stage III or IVA-B patients permitted)
+Clinical stage Tx, T1-T4, N1-3, M0
+Patients must have unresectable stage III or stage IV melanoma, either initial presentation or recurrent, that is of cutaneous origin or unknown primary origin and that is histologically diagnosed
+Patients must have unresectable metastatic stage IV melanoma or stage III intransit or regional nodal disease, and in the opinion of the institutional Principal Investigator (PI) is an acceptable candidate for ACT with high dose IL-2 (aldesleukin)
+Patients must have unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease and in the opinion of the principal investigator (PI) or treating co-investigator is an acceptable candidate for ACT
+Subjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 E or K mutation determined by pyrosequencing assay or Food and Drug Administration (FDA)-approved equivalent test, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria: \r\n* AJCC stage IV (Tany, Nany, M1a, b, or c) \r\n* AJCC stage III B or C with unresectable nodal/locoregional involvement
+Patients must have histologically or cytologically confirmed:\r\n* Extensive stage small cell lung cancer (SCLC) or \r\n* Stage IV (M1a or M1b according to American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition) large cell neuroendocrine non-small cell lung cancer (NSCLC) or \r\n* Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy \r\n** NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy
+Patient must have histologically or cytologically confirmed oral cavity squamous cell carcinoma of stage 2, 3, 4a, or 4b (by American Joint Committee on Cancer [AJCC] 7th edition [ed.])
+Clinical stage Tis or T1mi N0 M0
+Phase I: Patients must have histologically confirmed breast cancer (metastatic breast cancer [MBC]) that is human epidermal growth factor receptor 2 (HER2/neu) negative (as determined by local pathology or reference laboratory), and have disease that is metastatic (stage IV [TxNxM1]) or locally advanced and not amenable to potentially curative surgical resection (eg, clinical stage IIIB-C)
+Histologic diagnosis of unresectable stage III or IV melanoma\r\n* All melanomas regardless of primary site of disease will be allowed
+Patients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, or carcinosarcoma stage II, III, or IV with either optimal (=< 1 cm residual disease) or suboptimal residual disease
+For advanced (stage III/IV) Hodgkin's disease, patients must have failed an adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)
+Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer (NSCLC)
+Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with the appropriate tissue available for histologic evaluation.
+Completely surgically resected stage IIIb/c/d or stage IV melanoma within 12 weeks of participation in study.
+Patients must have advanced (stage III-IV) or recurrent histologically confirmed USPC
+Locally confirmed dMMR or MSI-H stage IV colorectal carcinoma
+Age ? 18 years with histologically confirmed diagnosis of melanoma and stage IIIB to IVM1c for whom surgery is not recommended.
+Histologically confirmed MBC, current stage IV.
+Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach.
+All Stage IV patients are eligible, irrespective of residual disease, after primary or interval debulking. Stage III patients are required to have visible residual disease after primary surgery. Patients with inoperable Stage III and IV disease are eligible
+Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by the American Joint Committee on Cancer (AJCC) 7th Edition staging criteria
+Patients must have non-bulky stage I or II disease by Ann Arbor classification\r\n* This staging excludes fludeoxyglucose F 18 (FDG)-PET evaluation\r\n* Patients who have stage I or II non-bulky disease based on diagnostic CT scan, but are upstaged to stage III or IV based on FDG-PET evaluation, are also eligible\r\n* Stage and bulk are assigned using measurements obtained prior to biopsy
+Diagnosed with stage IV Non-Small Cell Lung Cancer
+Subjects with FIGO Stage Ic, Stage II, Stage III, Stage IV, recurrent, or persistent (unresectable) histologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube carcinoma.
+Barcelona Clinic Liver Cancer (BCLC) Stage C disease (Llovet et al 1999), or BCLC Stage B disease.
+FIGO 2008 stage IIIA disease
+Single organ involvement (Stage 1-3 skin, Stage 1 upper GI, or Stage 1-2 lower GI)
+Multiple organ involvement (Stage 1-3 skin plus stage 1 upper GI, Stage 1-3 skin plus stage 1 lower GI, Stage 1-3 skin plus stage 1 lower GI plus stage 1 upper GI, Stage 1-3 skin plus stage 1-4 liver, or Stage 1 lower GI plus stage 1 upper GI)
+Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy
+Centrally confirmed Stage IV/M1 mTNBC
+Participants receiving alectinib in either Stage 1 or Stage 2: must be ALK positive as assessed by Food and Drug Administration (FDA) approved test and must not have received prior treatment for their advanced NSCLC.
+Patients with stage IV or recurrent/metastatic histologically confirmed non-small cell lung cancer (NSCLC)
+Histologically confirmed stage 1 through stage 3c primary adenocarcinoma of the breast
+Breast cancer, which at the time of study entry is either stage III (locally advanced) disease not amenable to curative therapy or stage IV disease; histological confirmation of recurrent/metastatic disease is encouraged but not required if clinical evidence of stage IV disease is available
+Patients must have HER2-positive stage II or III histologically confirmed invasive carcinoma of the breast; a minimum tumor size of 2 cm determined by physical exam or imaging (whichever is larger) is required
+Stage M1
+Histologically documented squamous cell carcinoma of the oropharynx (stage III-IV A,B)
+Distant metastases (stage IV C, any T, any N and M1)
+No prior systemic treatment for unresectable stage IIIB or IV NSCLC
+Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
+Metastatic (Stage IV) or recurrent NSCLC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
+Stage IV MSS CRC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
+Unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer staging system not amenable to local therapy.
+Stage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer 7th edition guidelines) with documented disease progression while on a PD-1 pathway targeted therapy.
+Has locally advanced/metastatic disease, i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer (AJCC) or have recurrent disease.
+Clinical stage ? T2b
+ISS Stage III; or
+ISS stage III; or
+Have advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;
+Histologically confirmed diagnosis of stage IIIB, IIIC or IVM1a melanoma eligible for complete surgical resection.
+Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma.
+Stage T3-4 disease
+Patients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligible
+Participant must have metastatic or advanced NSCLC (Stage IIIB or IV) that is not amenable to surgical resection or radiation or chemoradiation with curative intent at time of study screening.
+Either clinical or pathological Stage I (T1c), II, or III according to AJCC 7th edition
+Pathologically or cytologically confirmed NSCLC Stage IV Cancer (includes cytologically proven pleural effusion or pericardial effusion) or recurrent disease. Staging is based on American Joint Committee on Cancer (AJCC) Staging for NSCLC 7th edition (R12-4710)
+Patients must have histologically-confirmed stage IV TNBC (patients who had metastatic disease within 6 months of lumpectomy or mastectomy for treatment of TNBC may be excused from repeat biopsy)
+Untreated or previously received one treatment regimen for measurable unresectable stage III or stage IV melanoma (American Joint Committee on Cancer [AJCC] 2010) (for BRAF wild-type, and regardless of human leukocyte antigen [HLA] type); untreated or previously received up to two treatment regimens for measurable unresectable stage III or stage IV melanoma (AJCC 2010) (for BRAF mutant, and regardless of HLA type; If 2 prior regimens, one should be a BRAF inhibitor); this does not include any therapies given in the adjuvant setting
+Stages II bulky disease (defined as mass size of more than 10 cm), stage III, or IV (Ann Arbor staging); patients with stage I and stage II non-bulky disease are excluded from this study
+Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC
+Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)
+Pathologically (histologically or cytologically) proven diagnosis of NSCLC with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)
+Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage IV NSCLC.
+Male or female patients with metastatic, histologically- or cytologically-confirmed unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) of squamous histology (Staging per American Joint Committee on Cancer [AJCC], Edition 7). Mixed histology adenosquamous NSCLC will also be permitted.
+There must be histologic confirmation of high risk, adenocarcinoma of the colon defined as AJCC 7th Edition Stage IIIB or IIIC.
+Stage IIIb/C or Stage IV before complete resection
+Ann Arbor stage II to IV.
+Stage IIIb/IV NSCLC
+Patients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b, N2c or N3p16 negative oropharynx cancer or T1-2 any N hypopharynx cancer) including no distant metastases.
+Radiological stage T1-T2 N0 Mx/M0 disease.
+Stage II, III, or IV disease
+Prior treatment with immunotherapy for any stage NSCLC, including early-stage (neoadjuvant or adjuvant) disease
+Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that is unresectable or metastatic
+Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach
+Patients with initial diagnoses of stage IV disease
+New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
+Pathologically confirmed (histology or cytology) clinical Stage II, III, or IVA squamous cell cancer of the oral cavity (excluding lip). Subjects must be staged using AJCC Cancer Staging Manual Edition 7.0 (appendices 1 and 2).
+Staging MRI must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c;
+Confirmed diagnosis of stage IV NSCLC.
+Stage IV disease diagnosed within 6 weeks of randomization
+Stage IIIC colorectal cancer (T4a, N2a, M0) or (T3-4a, N2b, M0), or (T4b, N1- N2, M0) (per AJCC 7th ed).
+Have stage IV disease at the time of study entry (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition).
+Histologically documented, locally advanced or recurrent (stage IIIB who are not eligible for combined modality treatment) or metastatic (Stage IV) NSCLC
+Pre- or post-menopausal women with stage II-III breast cancer (American Joint Committee on Cancer [AJCC] 2002)
+Unresectable Stage III or Stage IV melanoma (AJCC 2010)
+Patients must have histologically confirmed advanced (FIGO Stage III or IV), persistent, or recurrent endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy. Histologic documentation of the recurrence is not required.
+Stage T3b or greater disease
+Stage IB (with a primary tumor >= 4cm), IIA, IIB, or IIIA (according to American Joint Committee on Cancer [AJCC] 7th edition); patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor
+Patients must have pathologically documented breast cancer which is stage IV
+Have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.
+Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system
+Stage IV (metastatic) breast cancer
+Previously untreated stage III/IV advanced or metastatic MEL (Part 1C only)
+For all Parts: The participant must have stage IV non-small cell lung cancer (NSCLC).
+Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test
+Participants with no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC
+Stage IV or locally advanced cancers for which no alternative therapies with proven survival advantage are available
+Subjects with histologically-or cytologically-documented NSCLC [squamous (SQ) or nonsquamous (NSQ)] who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)
+Subjects who are ipilimumab naïve with progressive unresectable stage III or stage IV melanoma who are either treatment naïve or may have been treated with up to 3 prior treatments for melanoma (e.g. chemotherapy, biologic or targeted therapy or interleukin [IL]-2)
+Histologic or cytologic confirmation of stage III or stage IV melanoma
+Cervical carcinoma of Stage 1B or less.
+Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria
+Prior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a 5-year disease-free interval; Stage II ovarian cancer must have a 2-year disease-free interval
+Patients must be HLA-A2+ and have histologically confirmed melanoma that is metastatic (stage IV) or unresectable stage IIIB/C and for which standard curative or palliative measures do not exist or are no longer effective
+Stage IV melanoma or stage III melanoma that is unlikely to be cured by surgery
+Patients must have adequate TIL (at least 40 x 10^6 cells at the pre-expansion stage)
+Subjects categorized to stage B (not applicable for transarterial chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
+Currently receiving or less than 28 days since ending systemic anticancer treatment for unresected stage IIIB to IV melanoma
+Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected
+Histologically confirmed Stage IIb, IIc, III melanoma
+No stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.
+Histologically confirmed melanoma that is considered surgically incurable with either: \r\n* Stage IIIc melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis\r\n* Stage IV melanoma (M1a, M1b, or M1c)
+Histologic diagnosis of unresectable III or stage IV metastatic melanoma
+Measurable Stage IIIA or IIIB disease
+Stage III A or B disease with minimum diagnostic evaluation within 6 weeks to include:
+Clinical stage T2-4a; N0/X; M0
+Patients enrolled in the single agent expansion stage must have a diagnosis of EOC, while patients enrolled in the combination dose escalation or expansion stage must have a diagnosis of melanoma, NSCLC, SCLC, RCC, BLC, or TNBC.
+For patients with EOC enrolled in the single agent expansion stage:
+For patients with melanoma enrolled in the combination dose escalation or expansion stage:
+The patient must have a pathologically confirmed (by histology or cytology) diagnosis of melanoma, which is currently Stage 3 (unresectable) or Stage 4 disease.
+For patients with NSCLC enrolled in the combination dose escalation or expansion stage:
+The patient must have a pathologically confirmed (by histology or cytology) diagnosis of NSCLC, which is currently Stage 3B or Stage 4 disease.
+For patients with SCLC enrolled in the combination dose escalation or expansion stage:
+For patients with RCC enrolled in the combination dose escalation or expansion stage:
+For patients with BLC enrolled in the combination dose escalation or expansion stage:
+The patient must have a pathologically confirmed diagnosis of urothelial BLC, which is currently Stage 4 disease.
+For patients with TNBC enrolled in the combination dose escalation or expansion stage:
+Histologically confirmed advanced (Stage IIIB/IV) NSCLC (all histologies including squamous and sarcomatoid)
+Stage IV HER2/Neu positive breast cancer patients who failed previous anti-HER2 targeted therapies
+Patients must have histologically confirmed metastatic melanoma with measurable, stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease.
+Ann Arbor stage 3 or 4 or stage 2 with bulky disease
+Naive or any number of prior systemic therapeutic regimens for unresectable stage III or stage IV melanoma, except prior BRAF or MEK inhibitor agents; this includes chemotherapy, immunotherapy, biochemotherapy, or investigational treatments; patients may also have received therapies in the adjuvant setting
+Stage IV or recurrent pancreatic cancer by imaging
+Female patients must have high risk resected stage I or 2 disease (papillary serous, clear cell, carcinosarcoma histology or grade 3), advanced stage (III or IV, all histologies) or recurrent endometrial cancer (all histologies); patients do not need measurable disease and can enroll following surgery
+Stage IV breast cancer, stage IV non-small cell lung cancer (NSCLC), stage IV sarcoma
+Participant has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior systemic platinum based chemotherapy.
+Participant has received more than one line of therapy for stage IIIB or IV disease
+Stage II, III, or IV disease
+Stage III/IV disease by Ann Arbor Staging
+Confirmed treatment-naive de novo cluster of differentiation (CD)20 positive (+) diffuse large B cell lymphoma (DLBCL), regardless of cell of origin, with stage II-IV disease, or stage I disease if 6 cycles of chemotherapy are planned
+Subject has BCLC stage B or C.
+Patients must have histologically or cytologically confirmed stage IIIB/C or stage IV oligometastatic melanoma; oligometastatic melanoma is defined as three or fewer areas of resectable disease excluding central nervous system and bone involvement; patients with cutaneous, mucosal, acral, ocular or unknown primary melanomas are eligible for enrollment; for patients with stage IV disease with distant lymph nodes (stage M1a), a maximum of three separate lymph node sites fit the definition of oligometastatic disease; resectable tumors are defined as having no significant vascular, neural or bony involvement; only cases where a complete surgical resection with tumor-free margins can safely be achieved are defined as resectable
+Subjects with either limited or extensive disease stage at the initial diagnosis
+Patients must have histologically confirmed MCC that is Stage III (IIIB) or Stage IV, as defined by the 2010 AJCC staging criteria for MCC. MCC of unknown primary is allowed.
+Stage T1-2N1-2c/T3-4N0-2c disease, as defined by American Joint Committee on Cancer (AJCC) criteria
+The participant has Stage IV NSCLC.
+Part A: NSCLC Stage IV (any type)
+Part B: NSCLC Stage IV (squamous and nonsquamous)
+Part C: NSCLC Stage IV in Japanese participants (squamous and nonsquamous)
+Patients with stage III, HER2-negative cancer in the contralateral breast
+Patients with stage I or II, melanoma who are not candidates for ipilimumab
+Stage II or III esophageal carcinoma according to the American Joint Committee on Cancer (AJCC) 7th edition staging
+Subject with stage IIIB to IVM1c melanoma for whom surgery is not recommended
+Completely resected Stage III melanoma
+Eligible patients must have appropriate staging studies identifying them as American Joint Committee on Cancer (AJCC) stage T1 (a, b, or c) or T2 (a, b, or c) adenocarcinoma of the prostate gland; the patient should not have direct evidence of regional or distant metastases after appropriate staging studies; histologic confirmation of cancer will be required by biopsy performed within 180 days of registration
+Documented evidence of NSCLC (Stage IIIB/ IV disease)
+Must have unresectable or inoperable stage IIIA or IIIB disease. Patients are considered unresectable or inoperable based on the judgment of the treating physician
+History of histologically-confirmed stage 0, I, II, or III breast carcinoma without evidence of disease at trial entry; participants with a resected local recurrence are eligible; site study physicians will review histology from documented pathology reports (which will be recorded in the Inclusion Criteria Case Report Form [CRF]); a separate consent will be obtained for release of medical records to document history of breast cancer diagnosis, staging, and treatment (which will be captured on the Medical History CRF); participants who have a documented history in their medical record of stage 0, I, II, or III breast carcinoma without evidence of disease at trial entry are eligible
+Patients must have Stage IIIB, IIIC or IV melanoma, which is unresectable/unresected or histologically confirmed diagnosis of metastatic malignant melanoma.
+Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) T1-T4 nodal stage N2 or N3 or a T3 or T4 primary tumor with any nodal stage
+Stage IV HER2 (+) breast cancer
+Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC
+Documented clinical stage IA, IB or IIA CTCL
+All grossly visible disease in the bladder must be fully resected and pathologic stage will be confirmed at the study institution
+Clinical American Joint Committee on Cancer (AJCC) stage II-III (AJCC, 7th ed.) with plans to be treated with concurrent chemoradiotherapy\r\n* Recurrent non-small cell lung cancer is allowed, provided the intent of the current treatment is curative and there has been no prior radiation to the thorax\r\n* Prior chemotherapy, immunotherapy, or targeted therapy is permitted as long as patients have recovered from prior toxicities to grade =< 1
+Histologic or cytologic proof of surgically unresectable stage IV malignant melanoma - including that of uveal and mucosal origin\r\n* Note: biopsy can be of locoregional disease in setting of clinically evident stage IV disease; a biopsy of the primary tumor alone does not fulfill this requirement
+Metastatic disease (Stage IV) or bilateral breast cancer
+Histologically confirmed surgical diagnosis of stage IIIC or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; patients with stage III cancer must have had peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis; NOTE: Histologic confirmation of the primary tumor is required; eligible histologies include serous, endometrioid, clear cell, mucinous, transitional cell, undifferentiated, or mixed carcinoma
+Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
+Patients must be stage 0-II based on Rai staging system; must have no indication for treatment for SLL per NCI-WG criteria
+Documented evidence of NSCLC (stage IIIB/IV disease)
+Subjects must have histologically-confirmed diagnosis of IDH1 gene-mutated cholangiocarcinoma Stage II, III, or IV (intra-hepatic, extra-hepatic and perihilar) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed histology are not allowed.
+American Joint Committee on Cancer (AJCC) (7th edition) stage IIb, III, or IV patients planned for resection of the primary tumor \r\n* > 5 cm in greatest dimension\r\n* Intermediate or high-grade \r\n* Superficial or deep
+Patients must have biopsy proven metastatic NSCLC (stage IV)
+Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
+Participants must have histologically confirmed hormone receptor positive (HR+), human epidermal growth factor 2 (HER2) negative stage II or stage III invasive breast cancer; evaluation for metastatic disease is not required in the absence of symptoms
+Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
+Stage III or IV cancer, other than breast cancer, in =< 5 years prior to registration
+Have metastatic disease (stage IV) confirmed surgically, by imaging or pathologically
+Stage Tis, T1, or T2 laryngeal squamous cancer as defined by American Joint Commission on Cancer (AJCC) 2007 staging system
+Direct laryngoscopy showing no evidence of greater than stage II true glottic larynx cancer
+Evidence of fixed vocal cord (stage cT3)
+Evidence of thyroid or soft tissue invasion (stage cT4)
+Evidence of positive nodal disease (stage N1)
+Cancer should be staged via American Joint Committee on Cancer (AJCC) as stage II, III, IVa, or IVb
+Memorial Sloan Kettering Cancer Center (MSKCC) pathologically-proven diagnosis of locally advanced stage III not amenable to definitive, curative treatment or stage IV or recurrent non-small cell lung cancer
+Clinical stage T1N0M0 (by American Joint Committee on Cancer [AJCC] 2010 criteria)\r\n* Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or micronodular features must be =< 1 cm
+No stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.
+FIGO stage IA1, IB2, II, III or IV disease
+Stage III/IV disease (stage II is also eligible if disease is not encompassible within a single radiation field)
+Histologically confirmed metastatic breast cancer (MBC), current stage IV
+Has a histologically-confirmed, unresectable or metastatic (Stage IV American Joint Committee on Cancer [AJCC seventh edition]) colorectal cancer (CRC)
+Must not have received prior systemic chemotherapy for Stage IV CRC
+With histologically or cytologically confirmed recurrent or refractory unresectable Stage IV gastric or gastro-esophageal junctional adenocarcinoma (according to American Joint Committee on Cancer/Union Internationale Contre le Cancer [UICC] 7th edition) and whose disease progressed after one or two prior chemotherapy regimen(s) involving both fluoropyrimidines and platinum
+PART A: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the American Joint Committee on Cancer [AJCC] staging manual)
+PART B: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the AJCC staging manual)
+Patients with stage IV HER2+ breast cancer treated to:\r\n* No evidence of disease (NED), or \r\n* Stable bone only disease after definitive therapy
+Ann Arbor stage IIB, IIIB, IVA, or IVB
+Diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC, or IV)
+Patients must have locally advanced unresectable stage IIIC or metastatic stage IV cancer with either progression to prior therapy or a newly diagnosed cancer that does not have an available treatment with curative intent
+Patients must have histologically confirmed melanoma with BRAF^V600 mutation; patients must have stage IIIC or stage IV disease
+Patients who are categorized under Barcelona-Cl?nic Liver Cancer (BCLC)-C stage
+Patients must have histologically confirmed diagnosis of stage IV metastatic melanoma positive for BRAF V600E mutation by either the COBAS test or other Clinical Laboratory Improvement Amendments (CLIA) approved assay
+Stage II (not candidates for local x-ray therapy), III, or IV disease by the Ann Arbor Classification
+Stage III patients must have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery.
+Patients with early stage disease (FIGO Stage I, IIA, IIB or IIC)
+Patients with synchronous primary endometrial cancer unless both of the following criteria are met: 1) stage <2 2) less than 60 years old at the time of diagnosis of endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade 3 endometrioid adenocarcinoma OR ? 60 years old at the time of diagnosis of endometrial cancer with Stage IA grade 1 or 2 endometrioid adenocarcinoma. Patients with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium are not eligible.
+Histologically confirmed stage III (unresectable) or stage IV melanoma
+Stage IV disease by AJCC criteria (7th edition).
+Patients with histologically documented diagnosis of advanced stage IV or unresectable stage III mucosal or cutaneous melanoma are eligible
+Adequately treated stage I or II cancer from which the patient is currently in complete remission
+Clinical stage IB (>= 4 cm per computed tomography [CT]), stage IIA/IIB, or stage III (N0-2) amenable to surgical resection
+Patients must be without visceral or bone involvement with metastatic breast cancer on physical exam or any diagnostic study; patients with extensive nodal involvement classified as stage IV disease, are eligible
+PARTS A AND B: Patients with Hodgkin lymphoma (HL) are eligible for both the phase 1 and 2 portions, if they are in one of the following categories:\r\n* Primary refractory disease (i.e. no prior CR) \r\n* Very early relapse (< 6 months from the end of initial therapy, including chemotherapy ± radiation)\r\n* Advanced stage (III or IV) at diagnosis who relapse less than one year from the end of initial therapy\r\n* Note that patients with low-stage disease (IA or IIA) at initial diagnosis, who were treated with radiation alone or fewer than four cycles of chemotherapy will NOT be eligible
+Barcelona Clinic Liver Cancer (BCLC) stage C, and those with BCLC-B stage who cannot tolerate or failed transarterial chemoembolization (TACE)
+Stage IIIB (AJCC Stage IIIB - Any T,N3M0 or T4N2M0) or Metastatic (AJCC Stage IV- any T, any N, M1), progressive, recurrent or refractory NSCLC. Patients may not be eligible for other curative intent treatment (e.g., surgical resection). For the purpose of eligibility for this trial, the above-cited disease states are defined as follows:
+Clinical stage T1-4/N0-3/M0 at presentation (patients with T1a/bN0 tumors will not be eligible)
+Stage IV (metastatic) breast cancer
+Metastatic (stage IV) disease (including involvement of the colon, adrenals, or kidney, or radiographic evidence of peritoneal seeding or pulmonary metastases)
+Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)
+Stage II or III disease by the American Joint Committee on Cancer (AJCC) 7th edition
+Patients must have stage IV breast cancer
+Stage IB, II-A, II-B, III and IV
+Unresectable stage III/IV melanoma
+STEP 1 ENROLLMENT: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th Edition stage IV NSCLC
+STEP 2 ENROLLMENT AND RANDOMIZATION: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th edition stage IV NSCLC
+Histologically confirmed Stage III (unresectable)/Stage IV melanoma
+Stage 3 or 4 disease without evidence of distant metastases
+International Association for the Study of Lung Cancer (IASLC) version 7, stage IV disease; or recurrence after prior surgery or radiotherapy
+Patient's disease must be pathological N-stage positive
+Patient must not have pathologically N stage negative disease
+American Joint Committee on Cancer (AJCC [2009]) stage IIIC cutaneous melanoma rendered free of disease by surgical resection no greater than 90 days prior study enrollment; patients with unknown primaries will be eligible for this trial; patients with a history of resected stage I or II cutaneous melanoma who subsequently have their first disease recurrence meeting the criteria for stage IIIC disease will also be eligible for this trial
+Patients with a history of stage III melanoma (any primary melanoma with locoregional nodal/subcutaneous disease) treated with surgical resection who subsequently have disease recurrence meeting the criteria for stage IIIC disease
+Completely resected histologically confirmed high-risk [Stage IIIa (LN metastasis more than 1 mm), IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.
+Have stage IA, IB or IIA: T1 or T2 (patches or plaques) with measurable lesions
+Stage IIB or greater CTCL
+Advanced stage NSCLC (stage IVa [malignant pleural effusion (is now staged as stage IVa by the most recent staging system), or stage IV, or recurrent disease])
+Biopsy-proven invasive adenocarcinoma of the rectum, stage T3-4 and/or node-positive (American Joint Committee on Cancer [AJCC] stage II or III) per AJCC staging manual, 7th edition; patients with M1a rectal cancer (“metastasis confined to one organ or site [e.g., liver, lung, ovary, non regional node]\), stage IVA disease per the AJCC staging manual, 7th edition, are also eligible; for the purpose of this study, a tumor is located in the “rectum” when its distal edge is located =< 12cm from the anal verge; the distal edge of the tumor can be delineated by digital examination or endoscopic examination, including colonoscopy, although rigid proctoscopy is preferred
+Patients with recurrent, inoperable stage III, IV, M1a, b or c melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (American Joint Committee on Cancer [AJCC]); previously treated with any form of therapy (including chemotherapy, radiation therapy, immunotherapy or surgery) for either metastatic, relapsed, or primary melanoma are eligible for this trial, provided the previous treatment was completed > 30 days prior to enrollment
+Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma
+Histologically or cytologically proven B-cell malignancies; either Burkitt leukemia or B-AL (= Burkitt leukemia = L3-AL), or diffuse large B-cell NHL, or aggressive mature B-cell NHL non otherwise specified or specifiable (phase III)\r\n* Stage III with elevated LDH level (B-high) (LDH > twice the institutional upper limit of the adult normal values [> Nx2]), any stage IV, or B-AL (phase III)
+Clinical stage T2-T4a N0/X M0 disease
+Histological diagnosis:\r\n* Histologically proven diagnosis of testicular seminoma\r\n** Histologically confirmed seminomatous germ cell tumor of the testis categorized as either \classical\ or \anaplastic”\r\n* Stage I disease\r\n** Any pT N0 M0 S0-3 (American Joint Committee on Cancer [AJCC], 7th Ed.)\r\n* Stage IIA or IIB disease\r\n** Any pT N1 M0 S0-3 (AJCC, 7th Ed.)\r\n** Any pT N2 M0 S0-3 (AJCC, 7th Ed.)\r\n** (At the discretion of the principal investigators, bulky stage IIB may be excluded from the study, according to National Comprehensive Cancer Center Guidelines)
+Stage IV disease according to the 7th Edition of the American Joint Committee on Cancer staging system
+Extent of disease: stage I - IV; patients with nodular histology mantle cell lymphoma must have Ann Arbor stage III or IV disease to be eligible\r\n* Patients with mantle zone type histology will not be eligible\r\n* Patients with other mantle cell histologies are eligible regardless of stage
+Patients with biopsy proven stage IIIC/IV epithelial ovarian cancer, primary peritoneal, fallopian tube carcinoma; if a core biopsy is not possible, fine-needle aspirate showing adenocarcinoma is acceptable in the setting of a pelvic mass and presence of metastasis outside the pelvis measuring at least 2 cm, regional lymph-node metastasis or proof of stage IV disease, and ratio of cancer antigen (CA) 125 to carcinoembryonic antigen (CEA) greater than 25; if CA 125 to CEA ratio is 25 or lower, barium enema, gastroscopy, and mammography must be negative
+Stage III with elevated LDH level (\B-high\), [LDH > twice the institutional upper limit of the adult normal values (> Nx2)] or any stage IV or B-AL.
+Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria
+At least three years since colectomy with IRA/proctocolectomy with pouch, and demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 Staging System (Appendix B) and summarized as follows: Stage 1: 10-25 polyps, all < 5 mm Stage 2: 10-25 polyps, at least one > 1 cm Stage 3: >25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high grade dysplasia, even if completely removed. [Note: For staging purposes only.]
+Intra-abdominal desmoid disease, stage III or IV
+Histologically confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IV
+Stage II, III, and IV disease by Ann Arbor classification
+Histologic or cytologic diagnosis of pancreas adenocarcinoma advanced or recurrent (stage III or IV) that is unresectable; histologic or cytologic pathology from any prior surgery is sufficient for diagnosis
+Pathologically confirmed diagnosis of Stage IIIB / IV adenocarcinoma of the lung.
+Histologically or cytologically confirmed soft-tissue sarcoma, excluding alveolar and embryonal rhabdomyosarcoma, well- and dedifferentiated adipocytic sarcomas, Ewing’s, osteosarcoma, or gastrointestinal stromal tumor; American Joint Committee on Cancer (AJCC) (6th Edition) Stage III or T2a Stage II or Stage IV treatment naive patients planned for resection of the primary tumor, with resectable metastatic disease
+Women with stage IA or IB1 cancer
+Clinical stage 2 or greater with localized disease
+Patients must have histologically or cytologically confirmed melanoma stage III/IV, unresectable
+Histologically or cytologically confirmed non-small cell cancer of the lung (NSCLC) stage IV (accordingto AJCC Staging 7th Edition);
+Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=] 7 centimeters [cm])
+Ann Arbor Stage I disease
+Histologic/cytologic proof of stage IV malignant melanoma not amenable to surgery
+Stage IV breast cancer.
+Stage 4 gastrointestinal GVHD as per Seattle-Glucksberg criteria
+Stage IV disease
+Patients with American Joint Committee on Cancer (6th edition, 2002) stage IV cancer with distant metastases
+Patients with American Joint Committee on Cancer (AJCC) seventh edition stage 4 metastatic non-small cell lung carcinoma
+Patients may have active mediastinal disease in N2 nodal stations if he/she has not received prior mediastinal RT\r\n* No restriction on prior T or N stage for patients who develop M1 disease at some point after initial diagnosis of stage I-III lung cancer and treatment
+Dose-Escalation Stage:
+Expansion Stage:
+Stage IV (M1), Stage IA, and lymph node negative breast cancer.
+Any evidence of nodal positivity beyond pathologic stage of pN0(i+)
+Has extensive-stage disease defined as Stage IV (T any, N any, M 1a/b) by the American Joint Committee on Cancer (AJCC), Seventh Edition
+For Melanoma Subjects: Have histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic (Stage IV) melanoma not amenable to local therapy, and irrespective of PD-L1 status
+Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.
+Stage IV disease, confirmed by biopsy or unequivocal radiographic evidence (note: staging scans are not required, but should be performed at treating physician discretion in accordance with standard guidelines)
+Patient must be American Joint Committee on Cancer (AJCC) stage III (T3N0, T1-2N1) or stage IVa (T1-4N2-3M0, T4N0-1 M0) or stage IVb (unresectable disease) and be either unresectable or borderline resectable
+Patients with Rai stage III-IV - OR - Patients with Rai stage 0-II
+Patients with histologically documented metastatic melanoma with:\r\n* (Metastatic disease cohort) measurable disease, stage IIIB, IIIC (in transit lesions with or without nodal metastases) that includes lesions accessible for biopsies or IV M1B\r\n* (Adjuvant cohort) subjects who are no evidence of disease (NED) and stage III or IV; this includes patients with stage IV disease resected to NED; stage IIB or IIC patients will be enrolled after review and approval by the PI
+Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.
+Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer
+Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage IA2, or stage IB1 disease
+FIGO stage II-IV;
+Pathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IV
+Stage IIIB or Stage IV NSCLC who are not candidates for multimodality treatment and have received at least 1 line of standard platinum-based therapy:
+Unresectable stage lll or IV, histologically confirmed diagnosis of one of the following solid tumors:
+Has a diagnosis of Stage IV rectal or rectosigmoid cancer with any multifocal metastases or single site metastasis with tumor size of > 2 cm (Intraoperative incidental finding or preoperative suspicion of Stage IV cancer with isolated (single site) metastasis (? 2 cm) or limited metastases (?3), with largest lesion ? 2 cm in size, does not exclude the subject).
+Another previous or current invasive malignancy within the last 2 years, with the exception of curatively treated stage Ia cervical carcinoma, or resected stage Ia endometrial cancer, and noninvasive nonmelanoma skin cancers
+Patient must have histologically or cytologically confirmed diagnosis of stage III melanoma inoperable/not amenable to local treatment or stage IV melanoma.
+Histological or pathologically confirmed stage IV adenocarcinoma of the colon.
+Subject has unresectable stage B (intermediate), or C (advanced) Hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging.Stage B subjects must have progressed after, or are not eligible for curative resection, transplantation, embolic, or ablative therapies
+Histologically confirmed, AJCC stage II or III breast cancer
+Stage IB-IIIA
+Limited stage SCLC appropriate for definitive treatment with chemoradiation
+Stage T1-4, N0-3, M0
+Adequately treated stage I cancer from which the subject is currently in remission
+Stage II, III or IV cardiac failure
+Histologically confirmed squamous advanced NSCLC (Stage IV).
+Histological diagnosis of unresectable American Joint Committee on Cancer (AJCC) stage III or stage IV, v-raf murine sarcoma viral oncogene homolog B1 V600E/K mutation (BRAFV600E/K) mutant melanoma by a Clinical Laboratory Improvement Assessment (CLIA) approved test
+Unresectable Stage III or IV disease
+Has locally advanced or metastatic disease (Stage IIIb or Stage IV) with radiographically or clinically evaluable lesions.
+Participants must have received 1 prior platinum-based chemotherapy regimen (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb or Stage IV) disease followed by documented progressive disease (PD).
+The patient must have clinical stage T1-4, N0-3, M0-1, stage II-IVC carcinoma as per the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual; patients with T1N0M0 will be ineligible; patients with metastatic disease with a limited metastatic burden are eligible if obtaining local control is determined by their treating oncologist to be an important therapeutic goal
+Patients with T1N0M0 stage I disease
+Disease may be stage I, II, III or IVA (as long as it is deemed resectable by the surgical team)
+Inclusion Criteria\n\n          -  Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC\n             (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer\n             staging criteria).\n\n          -  Measurable disease according to RECIST v.1.1.\n\n          -  An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.\n\n          -  BDX004 Positive Label.\n\n          -  Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or\n             biologic therapy for metastatic NSCLC. Subjects may have previously been treated with\n             postoperative adjuvant chemotherapy for early stage lung cancer or chemo radiotherapy\n             for locally advanced disease provided this was completed at least 6 months prior to\n             enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion\n             Criteria\n\n          -  History of severe allergic or anaphylactic reactions or hypersensitivity to\n             recombinant proteins or excipients in the investigational agent or erlotinib.\n\n          -  History of known brain metastases.\n\n          -  Prior treatment with any other investigational drug or biologic agent within 5 half\n             lives prior to randomization, or any investigational device within 2 weeks prior to\n             randomization.\n\n          -  Any unresolved toxicity from previous radiation therapy.\n\n          -  Significant cardiovascular disease, including:\n\n               -  Echocardiogram (ECHO) or multiple gated acquisition (MUGA) showing left\n                  ventricular ejection fraction of less than 55%.\n\n               -  Cardiac failure New York Heart Association class III or IV.\n\n               -  Myocardial infarction, severe or unstable angina within 6 months prior to\n                  randomization.\n\n               -  History of serious ventricular arrhythmia (ie, ventricular tachycardia or\n                  ventricular fibrillation).\n\n               -  Significant thrombotic or embolic events within 3 months prior to randomization\n                  (significant thrombotic or embolic events include but are not limited to stroke\n                  or transient ischemic attack).\n\n               -  Any uncontrolled or severe cardiovascular disease.\n\n          -  History of prior malignancy within 3 years prior to randomization (except for\n             adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or\n             cervix, superficial bladder cancer, or early stage prostate cancer, without evidence\n             of recurrence).\n\n          -  Radiographic evidence of interstitial lung disease.
+Patients with FDG-avid and pathologically proven stage IIA-IIB or IIIA-IIIB non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
+Patients with stage I or stage IV disease, including malignant pleural or pericardial effusion
+Patients selected for this study will have clinical stage I or II NSCLC; subjects with evidence of enlarged N2 nodes by routine computed tomography (CT) scan imaging or those with clinical stage III or IV NSCLC are excluded
+Patients with operable, T2-4, N0-3, M0, T1N1 breast cancer (stage IIA, IIB, IIIA, IIIB and IIIC) with minimum tumor size of 2 cm
+For Phase II: Histological diagnosis of BRAF V600E/K melanoma, unresectable stage III or stage IV, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2011; must have measurable disease, and no prior systemic treatment for locally advanced or metastatic melanoma; previous local therapy is allowed; previous systemic treatment for any stage III disease that was subsequently rendered NED (no evidence of disease) by surgery is allowed except for ipilimumab and BRAF inhibitors; patients with resectable disease who do not want surgery for any reason are also allowed; measurable disease is defined as least one lesion that can be accurately measured in two dimensions with both diameters >= 1.0 cm; for computed tomography (CT)/magnetic resonance imaging (MRI) evaluations, an effective slice thickness is required of less than or equal to 5 mm; for slice thickness greater than 5 mm, both diameters must be greater than or equal to 2.0 cm at baseline
+Patients with mycosis fungoides or Sezary syndrome must have stage IIb-IV disease (by International Society of Cutaneous Lymphoma [ISCL]/European Organization for Research and Treatment of Cancer [EORTC] criteria)
+Patients with advanced stage NSCLC who are candidates for single or multi-agent first-line therapy
+Metastatic disease (Stage IV) OR
+Patients with cytologically or histologically confirmed non-small cell lung cancer (NSCLC) – locally advanced, stage IIIB OR stage IV or stage IVM1A (malignant pleural or pericardial effusion or pleural implants) OR recurrence after primary surgery or radiotherapy (refer to 2010 American Joint Committee on Cancer [AJCC] staging, 7th edition [Ed])
+Locally advanced (Stage 3B) or metastatic (Stage 4) disease
+Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).
+Histological diagnosis of NSCLC or MPM; pts must have clinical and/or pathological evidence of pleural spread or stage III/IV MPM
+Pts undergoing extrapleural pneumonectomy without PDT for MPM or stage IV (M1A) NSCLC (after American Joint Committee on Cancer [AJCC] staging change 2010) or stage IIIB (before staging change) with malignant pleural effusion treated at Ohio State University (OSU) from 2005-2012
+Histologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).
+Histologically-confirmed NSCLC Stage IV disease (according to the seventh edition of the lung cancer staging system)
+Diagnosed with radiologically and biopsy or cytology confirmed inoperable perihilar cholangiocarcinoma Bismuth Tumor Stage III/IV
+Histologically confirmed diagnosis of stage IV, HER2 negative breast cancer
+other adequately treated Stage 1 or 2 cancer currently in complete remission
+Have a history of Stage IV Colorectal Cancer (CRC) with metastases to the liver only
+Clinical stage T2-T4a, N0/x, M0 disease
+Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)
+Patients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.
+Patient must have measurable stage IV disease (includes M1a, M1b stages or recurrent disease) (according to the 7th edition of the TNM classification system); however, patients with T4NX disease (stage III B) with nodule(s) in ipsilateral lung lobe are not eligible, because such patients were not included in historical controls
+Histologically confirmed surgically incurable and unresectable Stage IIIC or Stage IV (AJCC) melanoma
+Patients must have histological or cytological confirmed melanoma that is metastatic or unresectable stage IIIc and clearly progressive.
+Patients with confirmed unresectable Stage IIB or Stage III non-small cell lung cancer of any histologic-subtype appropriate for definitive concurrent chemotherapy and radiation as determined by multi-disciplinary assessment; all detectable tumor should be encompassable by radiation therapy fields, including both the primary tumor and the involved regional lymph nodes
+Patients with histologically documented diagnosis of advanced stage IV or unresectable stage III melanoma are eligible
+Stage IB-IIIA
+Patients must have a histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of advanced stage (stage III or IV) or recurrent endometrioid endometrial cancer
+Stage IV disease at the start of first-line chemotherapy
+Has received prior treatment with chemotherapy or biologic therapy for stage IV NSCLC.
+Patients with histologically proven melanoma with metastasis that is unresectable Stage III or Stage IV. This will include bulky stage III and M1-3. Patients with melanoma with documented metastases to the brain are eligible.
+Stage III or IV disease at any time in the past (Ann Arbor Staging System for Non-Hodgkin’s Lymphomas)
+Patients with stage IV disease with no more than five metastases in no more than two visceral organ sites will be eligible; if a multidisciplinary tumor board determines trial entry for an individual patient with stage IV exceeding this number of metastases is appropriate, that patient can be enrolled
+Histologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in largest diameter (cT1-3) by MRI
+Participants with cT4 or cN3 stage breast tumors
+Metastatic (Stage IV) breast cancer
+Malignancies other than non-squamous NSCLC successfully treated within 3 years prior to randomization (with the exception of certain early-stage cancers)
+Resected, histologically proven, cutaneous melanoma determined to be Stage IIb, IIc, or III; according to the American Joint Commission of Cancer Staging, 7th edition
+No prior treatment for Stage IV squamous NSCLC
+Histologically confirmed invasive breast carcinoma, with all of the following characteristics: (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm) in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer; (iii) Documented absence of distant metastases (M0)
+Participants with cT4 or cN3 stage breast tumors
+Ann Arbor Stage II, III, or IV
+Histologically documented Stage IV ductal adenocarcinoma of the pancreas
+Prior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer
+Histologically documented Stage IV ductal adenocarcinoma of the pancreas
+Prior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer
+Stage II, III or IV disease
+Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma
+Histologically or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC)
+Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC
+All patients must be either Stage IIIb/c or Stage IV according to the American Joint Committee on Cancer (AJCC) (7th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable in order to be eligible. Please refer to the AJCC Cancer Staging Manual, 7th edition for a description of tumor, lymph node, metastasis and staging.
+Patients must have histologically or cytologically confirmed metastatic melanoma; this includes American Joint Committee on Cancer (AJCC) stage IV or advanced/inoperable stage III; this also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases
+Subjects with a confirmed or suspected diagnosis of stage IA to stage IIIA non-small cell lung cancer scheduled for a lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)5;
+Cervical carcinoma of Stage 1B or less.
+Histologically or cytologically documented, locally advanced or metastatic (i.e., stage IIIB not eligible for definitive chemoradiotherapy, stage IV, or recurrent) NSCLC (per the American Joint Committee [AJCC] staging system)
+Women with unilateral stage I or II BCRL
+Stage III lymphedema
+Relapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior treatments.
+Stage II disease with bulky disease (? 7cm lesion), Stage III, or Stage IV disease
+Stage IV or Recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer (IASLC) classification)
+Patients with stage IA to IIB disease; select patients with resectable stage IIIA disease (T3N1, T4N0, T4N1) will also be eligible if approved by the principal investigator (PI)
+This trial will include subjects with stage IB-IVB MF/SS (maximal stage since diagnosis will determine eligibility), and who have relapsed, are refractory, or progressed after at least one standard systemic therapy; current disease stage at time of entry will also be documented but will not be used for eligibility
+Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
+Pathologically confirmed of advanced and/or metastatic stage IIIb/IV non-small cell carcinoma of lung
+Histologically or cytologically documented advanced NSCLC who have Stage IIIB/Stage IV disease, or recurrent disease following radiation therapy or surgical resection or advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;
+Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive (cohort A) or mutation-negative (cohorts B and C)
+Stage 4c metastases.
+Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)
+Diagnosis of stage IV non-small cell lung cancer, or stages II-III NSCLC that cannot be treated curatively with standard techniques
+Resectable disease-clinical stage I (T/0/N0miT1N0-N0mi), IIA-IIIA (T2 N0/T3N0 or T1-3 N1-N2a) or unresectable disease – clinical stage IIIB/IIIC (T4 or T1-3 N2b-3); no evidence of metastatic disease
+Histologically documented recurrent or advanced (Stage IV) NSCLC
+Patients must have histologically confirmed recurrent stage III or stage IV melanoma (AJCC 7th edition classification); cutaneous melanoma, ocular or mucosal melanoma will be eligible
+Histologically confirmed stage IV or unresectable stage III melanoma with documented BRAF V600 mutation
+Histologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC)
+No prior treatment for unresectable Stage IIIB or IV NSCLC
+Histologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent metastatic squamous NSCLC with Fibroblast growth factor receptor 1 (FGFR1) gene amplification by central laboratory testing. Arm C- recurrent after local therapy or unresectable MPM with measurable lesions. For specific arms the following requirements: Arm A: Subjects who have received no prior therapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note, to avoid any undue delay of initiating systemic chemotherapy for these subjects with newly diagnosed metastatic disease, it is allowed to initiate the first cycle of chemotherapy while eligibility for the study is still being determined, as long as the first dose of GSK3052230 is given no later than Cycle 2 Day 1 of chemotherapy. In addition, subjects with Stage IIIB or Stage IV disease and recurrence after previous NSCLC that has been treated with surgery and adjuvant chemotherapy or a radio- chemotherapy regimen with curative intent are eligible, provided 6 months has passed since this treatment ended. Arm B: Subjects who have documented tumor progression (based on radiological imaging) or intolerability after receiving at least one prior line of platinum containing combination chemotherapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note: Prior treatment should not include docetaxel but may have included paclitaxel. Arm C: Subjects who have received no prior systemic therapy for MPM.
+Locally advanced or metastatic non-small cell lung cancer (stage IIIB or IV by AJCC 7th)
+Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E or V600K mutation-positive by the local laboratory. Subjects with ocular or mucosal melanoma are not eligible
+Advanced (FIGO stage III or IV), recurrent or metastatic disease.
+Second line or greater/Refractory/Relapsed, Stage I, Stage II, Stage III
+Any stage disease is allowed
+Presumed early stage ovarian cancer
+Recurrent, satellite or in-transit locally advanced cutaneous or subcutaneous melanoma metastases (i.e., AJCC Stage IIIB, IIIC or Stage IV M1a with no active nodal metastases)
+Stage must be classified as one of the following:\r\n* Ann Arbor stage IA or IIA with:\r\n** Non-bulky mediastinal disease (< 33% mediastinal to thoracic ratio on chest x-ray [CXR])\r\n** < 3 nodal regions involved on the same side of the diaphragm\r\n** No “E” lesion
+Histological or cytological proven advanced (unresectable) or metastatic NSCLC as defined as stage IIIB (positive supraclavicular lymph nodes) not amenable to definitive chemoradiotherapy or stage IV NSCLC
+Inclusion Criteria for Both Stages:\n\n          -  Measureable disease per RECIST v1.1 with tumor accessible for biopsy\n\n          -  Adequate hematologic and end organ function\n\n        Inclusion Criteria for Stage 1:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Metastatic or inoperable, locally advanced, histologically or cytologically confirmed\n             invasive HR-positive HER2-negative breast cancer\n\n          -  Recommended for endocrine therapy, and cytotoxic chemotherapy not indicated at study\n             entry\n\n          -  Recurrence or progression following most recent systemic breast cancer therapy\n\n          -  Disease progression during or after CDK4/6 inhibitor treatment for metastatic disease\n\n          -  Postmenopausal according to protocol-defined criteria\n\n          -  Life expectancy >3 years\n\n          -  Available tumor specimen for determination of PD-L1 status\n\n        Inclusion Criteria for Stage 2:\n\n          -  ECOG performance status of 0-2\n\n          -  Ability to initiate treatment within 3 months after disease progression or\n             unacceptable toxicity on a Stage 1 regimen\n\n        Exclusion Criteria for Both Stages:\n\n          -  Significant or uncontrolled comorbid disease as specified in the protocol\n\n          -  Uncontrolled tumor-related pain\n\n          -  Autoimmune disease except for stable/controlled hypothyroidism, Type 1 diabetes\n             mellitus, or certain dermatologic conditions\n\n          -  Positive human immunodeficiency virus or hepatitis B or C\n\n          -  Severe infection within 4 weeks and/or antibiotics within 2 weeks prior to study\n             treatment\n\n          -  Prior allogeneic stem cell or solid organ transplantation\n\n          -  History of malignancy other than breast cancer within 2 years prior to screening\n             except those with negligible risk of metastasis/death\n\n          -  History of or known hypersensitivity to study drug or excipients\n\n        Exclusion Criteria for Stage 1:\n\n          -  HER2-positive breast cancer\n\n          -  Prior fulvestrant or cytotoxic chemotherapy for metastatic breast cancer, or certain\n             other agents as specified in the protocol\n\n          -  Unresolved AEs from prior anti-cancer therapy\n\n        Exclusion Criteria for Stage 2:\n\n          -  Unacceptable toxicity with atezolizumab during Stage 1\n\n          -  Uncontrolled cardiovascular disease or coagulation disorder, including use of\n             anticoagulants as specified in the protocol\n\n          -  Significant abdominal or intestinal manifestations within 6 months prior to treatment\n\n          -  Proteinuria
+Unresectable Stage III or Stage IV melanoma
+Histologically documented advanced (Stage IV) or recurrent squamous (Arms A and B) or non-squamous (Arms C, D, E, and F) non-small cell lung cancer (NSCLC)
+End-stage renal disease: requiring hemodialysis
+Stage II, III or IV (Ann Arbor Staging)
+Histologic diagnosis of melanoma with in transit metastasis stage IIIB, IIIC, or IV
+Part A2: Histologic or cytologic diagnosis of advanced Non Small Cell Lung Cancer (NSCLC), Stage IIIB with malignant pleural effusion or Stage IV, completed at least 1 prior systemic regimen, and eligible for erlotinib therapy.
+NSCLC: --Histologic or cytologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural effusion or Stage IV
+Participants must have clinical diagnosis of lung or bladder cancer; if the diagnosis of non-small cell lung cancer (NSCLC) or bladder cancer is confirmed, platinum-based chemotherapy must be planned either for neoadjuvant chemotherapy for stage II or above bladder cancer, or palliative therapy for stage III or IV bladder cancer or stage IV lung cancer regardless of patient participation in this study; stage II or above transitional cell carcinoma (TCC) patients and stage IV NSCLC patients that will receive platinum-based chemotherapy will be eligible for this study; patients with stage III or IV bladder cancer or stage IV lung cancer must have measurable lesion(s)
+Patients must have histologically or cytologically confirmed metastatic melanoma (includes American Joint Committee on Cancer [AJCC] stage IV or advanced/inoperable stage III; also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases)
+Barcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, or BCLC intermediate stage (B) hepatocellular carcinoma if treatment with transarterial chemoembolization is not considered appropriate
+The patient has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease
+The participant has Stage IV disease at the time of study entry.
+The participant is currently or has previously received chemotherapy for advanced (Stage IV) NSCLC.
+Early stage breast cancer (stage I [tumor size >= 1 cm], II and IIIA)
+Stage IV disease at the time of study entry
+Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay.
+Patients must have suspected International Federation of Gynecology and Obstetrics (FIGO) stage III or IV disease
+Histologically confirmed cutaneous melanoma with unresectable stage III disease, or stage IV disease by American Joint Committee on Cancer (AJCC) criteria
+Histologically or cytologically proven adenocarcinoma of the breast stages II-III, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2009
+Subject has end stage renal disease and requires chronic dialysis
+Initial presentation: stage IV or metastatic disease, enrolled prior to any cytoreductive therapy
+Ann Arbor stage I disease.
+Primary melanoma with the following Breslow thickness and stage:\r\n* =< 2 mm\r\n* Patients with recent (within 12 weeks) biopsy of primary melanoma that has not been widely resected will be eligible for study according to the above-specified criteria for tumor thickness and stage; if more than one biopsy was done for the primary melanoma, the window of 12 weeks will be counted from the date of the last surgery
+Histologically or cytologically confirmed Stage IIIB, IV (according to AJCC) or recurrent non small cell lung cancer (NSCLC) (non squamous histologies)
+Unresectable stage III or stage IV M1a/M1b/M1c melanoma including patients with uveal melanoma
+Barcelona Clinic Liver Cancer (BCLC) stage B
+Mycosis fungoides patients that have stage T2-4 N0-1 M0B0 disease
+Patient who have AJCC 8th edition Prognostic Stage Group II
+Dose escalation: Patients with metastatic melanoma with measurable, stage III (in transit lesions) or stage IVA, IVB or IVC disease (at least 2 measurable lesions/tumors; patients will be required to have one more lesion resent than the number the current dose level requires since one lesion will be left untreated
+Expansion cohorts: Patients with metastatic melanoma with measurable, stage III (in transit lesions) or stage IVA, IVB or IVC disease at least two measurable lesions/tumors
+Histologic diagnosis of unresectable stage IIIC or stage IV melanoma that is BRAF V600 mutation positive
+Inoperable or metastatic extra cranial stage III or IV disease
+Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a DNA sequencing method, and who have no acceptable standard treatment options
+Final American Joint Committee on Cancer (AJCC) stage IIa – IIIa (pathologic stage T0N1a-2a, T1N1a-2a, T2N1a-2a, T3N0-2a, all M0 status); pathological stage for all patients not receiving neoadjuvant chemotherapy; higher of the clinical or pathological T and N stage, if receiving neoadjuvant chemotherapy; patients with pathological N0 at the time of mastectomy are only eligible if biopsy-proven clinically N1 or N2 disease is documented prior to induction chemotherapy
+Advanced (stage IIIB or IV) lung adenocarcinoma diagnosed by biopsy of the primary or metastatic site (American Joint Committee on Cancer 7.0)
+Stage IV cancer
+Past history of treated (newly diagnosed or recurrent) breast, colorectal, prostate, gynecologic (only uterine and cervical) cancers (stage I, II, or III) or any stage lymphoma (Hodgkin’s or non-Hodgkin’s)
+Patients with stage IA1 disease who are LVSI negative
+Patients with >= stage IB2 disease
+Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed
+Patients must have histologically or cytologically confirmed stage I-III breast cancer (as defined by the revised, American Joint Committee on Cancer [AJCC] 7th edition criteria) and be at sufficient risk for tumor recurrence; staging studies to exclude metastatic disease are not required in asymptomatic patients; however, patients with findings considered suspicious for metastatic disease on any staging studies that are obtained need to be evaluated to exclude stage IV breast cancer
+PHASE I: Diagnosis of stage I to III breast cancer
+PHASE II: Diagnosis of stage I to III breast cancer
+Diagnosis of a solid tumor malignancy (any stage)
+PATIENT INCLUSION: Clinical diagnosis stage 4 solid or hematologic malignancy or nonresectable stage 3 gastrointestinal (Gi) cancer
+Experiencing their first, stage 0 – IIIA breast cancer diagnosis (either clinical or definitive early stage at enrollment)
+Survivors with a primary diagnosis of stage I-III breast, ovarian, uterine, or endometrial cancer
+Stage 3B BC
+Inflammatory or stage 4 BC
+Cancer stage: T1 - 4N x M0
+Diagnosed with in situ or metastatic breast, prostate or colorectal cancer (i.e. stage 0 or IV)
+Women diagnosed with early stage, resectable breast cancer (Stage 0, I, II, or III) prior to age 45, and are within 5 years of diagnosis
+A diagnosis of stage IV breast cancer
+Stage I-III
+Stage IV breast cancer
+Diagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatment
+Three populations of patients are eligible for enrollment:\r\n* Patients with early stage disease at diagnosis (stage I-II) who were treated with chemotherapy alone and relapsed with early stage disease (stage RI-II)\r\n* Patients with early stage disease at diagnosis (stage I-II) who were treated with chemotherapy alone and have early stage (stage RI-II) primary refractory disease (residual disease on a scan 1 month after the completion of initial therapy) without B-symptoms and with each area of disease less than 10 cm in size\r\n* Patients with early stage disease at diagnosis (stage I-II) who were treated with combined modality therapy (chemotherapy and radiation) who relapse with early stage disease (stage RIII) outside the prior radiation therapy field
+Ann Arbor stage III or IV disease at diagnosis or at relapse/refractory disease confirmation
+Stage IB-IVB MF/SS, and who have relapsed, are refractory, or progressed after at least one standard systemic therapy; maximal stage since diagnosis will determine eligibility; current disease stage at time of entry will also be documented but will not be used for eligibility
+Patients must have histologically or cytologically confirmed stage IV invasive breast cancer; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
+Ann Arbor stage III or IV disease (Cohort A only)
+Absolute neutrophil count ? 1500 per microliter Stages I and II, Arm C or Stage II Arm D:
+Patients must have pathologically confirmed stage IV or unresectable stage III melanoma; patients must not have disease that is suitable for local therapy, administered with curative intent
+Histologically confirmed diagnosis of early stage breast cancer (stage I-III)
+1-3 years post-completion of chemotherapy or/and radiation therapy for stage I-III breast cancer
+Diagnosed with stage III or IV colorectal cancer
+Diagnosed with stage I, II, or III (a/b) breast cancer
+Stage IV and/or metastatic solid tumor cancer diagnosis, or stage III pancreatic or lung cancer diagnosis
+Diagnosed with stage I-III lung cancer
+Any disease stage
+Stage II-III breast cancer
+Be diagnosed with breast cancer at stage 0, I, II, III or IV
+Clinical stage I EC
+Phase I: Diagnosis of primary pathologic stage 0–III cutaneous malignant melanoma
+Phase II: Diagnosis of primary pathologic stage 0–III cutaneous malignant melanoma
+Patients with end-stage renal disease defined as creatinine clearance of < 15mL/min and/or diagnosed with stage 5 chronic kidney disease
+Localized endometrial cancer (stage I and II); no evidence of stage III or IV disease
+Diagnosis of stage I to III breast cancer
+Patients with stage I-III breast cancer
+Diagnosed with stage 0, I, II, or IIIa breast cancer, confirmed by medical record
+Diagnosis of stage III, IV or recurrent gynecologic malignancy (uterine, ovarian, cervical, vulvar, vaginal, fallopian tube, primary peritoneal)
+Participants must self-identify as having a medical history of histologically confirmed stage 0, I, II, III breast cancer, or I with no evidence of metastatic disease
+Stage 5 chronic kidney disease or need for hemodialysis
+Have a history of stage I, II, or III breast cancer
+Metastatic breast cancer (stage IV)
+Mallampati IV
+As per medical record, early stage prostate cancer (pathologic stage 1-2 with Gleason score =< 8; or pathologic stage 3 with Gleason score =< 7)
+Patients must have evidence of histologically confirmed invasive breast cancer, stage I, II or III, and be at least 2 years post diagnosis
+As per self-report, a current caregiver to a patient with any site or stage of cancer
+Metastatic breast cancer (MBC) diagnosis – Stage IV
+DCG: Is an adult family member (at least 18 years old) of a patient with an advanced-stage cancer
+Diagnosed with stage 0-III hormone-receptor positive breast cancer (BCa)
+Metastatic (stage IV) BCa
+PATIENTS ONLY: Diagnosed with stage IV non-small cell lung cancer (NSCLC)
+Stage 3 or 4 under the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (IUCC) staging system OR patients with stage 1 or 2 disease who will receive radiation equivalent to patients with stage 3 or 4 disease
+Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers (“type I cancers”) as confirmed during surgical intervention for treatment
+Diagnosed with early stage (I-III) breast cancer, without evidence of metastatic disease
+Advanced stage (stage IV) or metastatic breast cancer diagnosis (screening for metastases with scans only needed if there is clinical suspicion for metastases)
+Patients with stage II – IV non squamous cell NSCLC who received at least 54 Gy of total planned thoracic radiation dose will be eligible; patients must have received at least one cycle of chemotherapy concurrently during the course of thoracic radiation; regimens allowed are platinum combinations with either etoposide or a taxane regardless of histology subtype; platinum with pemetrexed for patients with non-squamous NSCLC only; patients with oligometastatic stage IV cancer are eligible if they have received only one line of systemic therapy for their stage IV cancer prior to the concurrent chemoradiation phase
+Phase 1: Early stage (stage 1 and 2) CRC survivors who are 6 month or greater post-treatment
+Prior diagnosis of stage 0 to stage III breast cancer
+Women who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-8 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors); recruit women who have received one of the two most common stage I-IIIA chemotherapy regimens, either docetaxel/cyclophosphamide or doxorubicin/cyclophosphamide followed by paclitaxel to provide uniformity of prior treatment
+Tumor stage II or greater
+Have a diagnosis of breast cancer (BC) (stage I-III)
+Identified as the active or maintenance stage of exercise behavior
+Women with stage II or III breast cancer that will be scheduled to undergo a 4 to 6-week course of radiotherapy
+Confirmed diagnosis of metastatic or stage IV BC
+Diagnosed with stage I-III colorectal cancer
+Breast cancer stage I-III
+Stage I-III colorectal cancer (CRC).
+Histologic or cytologic proven breast cancer or colon cancer (stage I, II or III)
+Eligible disease(s)/stage(s): nasopharyngeal carcinoma, paranasal sinus cancers/any stage
+STAGE I
+STAGE II
+Stage I participants are ineligible
+Diagnosis of adenocarcinoma colorectal cancer (stage I, II, III, IV)
+Patients with early-stage breast cancer (stage I-III)
+Patients with stage IV breast cancer
+Patients with advanced or stage IIIC or IV breast cancer or other cancers
+Diagnosis of stage I-III cancers of the rectosigmoid colon or rectum
+Patients with stage IV disease will be excluded from the study
+Patients must have stage III or IV cancer diagnosis
+Newly diagnosed with high grade stage 2, any grade stage 3 or higher endometrial cancer in the past 6 months
+Primary family caregivers of cancer patients who are diagnosed with stage II-IV disease
+Stage II or III unilateral secondary upper extremity lymphedema (as defined by the International Society of Lymphology)
+Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; a patient with a diagnosis of stage III cancer or lymphoma is eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed
+Metastatic disease (Stage IV C)
+Women diagnosed with stage I-IV ovarian cancer
+Caregivers of patients who have been diagnosed with stage IV gastrointestinal (GI) cancer
+Diagnosis of cancer (any stage) for which active treatment (e.g., surgery, chemotherapy, and/or radiotherapy) has been completed within 2 months to 2 years
+Patient participants must have stage III, IV and/or recurrent NSCLC
+End stage renal disease (ESRD)
+Diagnosed with stage 0-III breast cancer within the past 3 years
+A diagnosis of breast cancer, stage I, II, or III
+Women with stage 0-III breast cancer who will be undergoing daily adjuvant radiation for 4-6 weeks (patients only)
+History of histologically or cytologically proven stage I-III breast cancer receiving intravenous chemotherapy on an every 14 days or every 21 days schedule
+History of stage 0-III breast cancer
+Diagnosed with stage I-II endometrial cancer
+Stage IV or stage IIIB cancer
+Has diagnosis of non-recurrent stage I-III breast cancer
+History of endometrial cancer stage I-IV > 6 months < 5 years, not currently receiving cancer treatment
+Stage I-III
+Stage IV breast cancer
+Have been diagnosed within one month with a pathologically confirmed advanced cancer who have an average of < 2 year (y) life expectancy (primary stage IV hepatobiliary, esophageal, colorectal, glioblastoma, gastric, pancreatic, melanoma, head and neck, or stage III or IV lung or pancreatic cancers) and are being treated at one of the participating hospital sites and speak English or Spanish
+PATIENT: Be diagnosed with an incurable and advanced-stage solid malignancy (stage IIIB, IIIC, or IV)
+SCREENING PHASE: Histologically proven stage I-III carcinoma of the breast
+SCREENING PHASE: Known metastatic (stage IV) breast cancer involvement
+INTERVENTION PHASE: Histologically proven stage I-III carcinoma of the breast
+INTERVENTION PHASE: Known metastatic (stage IV) breast cancer involvement
+History of stage 0-III breast cancer or stage I-III ovarian cancer; all antitumor therapies, excluding hormonal therapy, have been completed at least 60 days prior to enrollment
+Patients will be included if their initial stage was T1 N0 M0 or T2 N0 M0
+No evidence of distant metastasis representing stage IV metastatic disease
+No more than 4 prior cycles of chemotherapy for primary advanced (stage III or IV) epithelial ovarian, primary peritoneal, or fallopian tube cancer
+Have end stage renal disease
+Subjects with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapy
+Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy.
+Histological or cytological confirmation of Stage IIIb or Stage IV (unresectable) NSCLC
+Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease
+History of histologically or cytologically proven breast cancer at stage I, II and III, without evidence of distant metastasis
+History of histologically or cytologically proven breast cancer at stage I, II and III without evidence of distant metastasis
+Diagnosed with stage IV disease
+Stage III/IV cancer
+Diagnosis of stage III-IV epithelial ovarian cancer (EOC)
+Subjects with stage IV NSCLC (not recurrent or re-staged).
+Histologic or cytologic confirmation of head & neck cancer (stage I-IV) or non-small cell lung cancer (stage II & III)
+Patients with histologically confirmed invasive breast cancer, stage I - IV, treated at Lyndon B. Johnson General Hospital in the Harris Health System
+Stage I, II, and III prostate cancer
+T stage greater than clinical T1
+Diagnosis of stage 0 to III breast cancer
+Patients with T1 or T2 disease with N2 or T3N1-2 disease (stage IIIA) are eligible if they are medically inoperable; patients with T4 with any N or any T with N3 disease are eligible; radiographic evidence of mediastinal lymph nodes > 2.0 cm in the largest diameter is sufficient to stage N2 or N3 disease; if the largest mediastinal node is < 2.0 cm in diameter and this is the basis for stage III disease, then at least one of the nodes must be proven positive cytologically or histologically
+Have diagnosis of breast cancer stage IV
+Has metastatic disease (M1) Stage IV C
+Women diagnosed with stage IV ovarian cancer and who are hospice eligible
+Diagnosis of stage III or stage IV cancer
+Caregivers will be eligible for enrollment if they identify as the person who is the caregiver of a patient diagnosed with advanced cancer (stage IV, solid tumor)
+Have been diagnosed with stage I-III colon or rectal adenocarcinoma
+Stage 0-III invasive carcinoma of the breast
+Patients diagnosed with GOLD Stage IV Emphysema.
+STAGE 1:
+STAGE 2 PATIENT PARTICIPANTS:
+Diagnosis of stage I, II, or III ovarian cancer
+Patients with stage 0-III breast cancer, status-post surgery treated with standard chemotherapy/chemoprevention and/or radiation
+Metastatic disease (Stage IV C)
+History of stage I-III breast, gastrointestinal or gynecologic cancer
+Diagnosed with stage I-III cancer other than cancers of the brain or spinal cord (confirmed by patient self-report on the Health History Questionnaire; if patient is unable to confirm either the site of her cancer or that her stage of cancer is < stage IV, we will send a letter to her physician to confirm this criterion)
+Currently stage IV (metastatic) breast cancer on the basis of definitive imaging or biopsy with\r\nstable disease (scans within the past 2 months)
+T stage >= T3 (mass extending outside the bladder)
+Patients with end stage renal disease (ESRD) and/or on dialysis
+T stage: cTis – T2
+Pathologic stage IIIA, IIA or IIB, or large IB (defined as size >= 4cm); Note: IB tumors < 4cm are NOT eligible; stage IB cancer based on pleural invasion is not eligible unless the tumor size is >= 4cm
+Previous diagnosis of stage 4 cancer
+No measurable disease or suspected stage I or II ovarian cancer on preoperative imaging
+Have end-stage renal disease
+End Stage Renal Disease (ESRD)
+Patients with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosis
+Patients who are currently undergoing treatment (primary or consolidation) for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer or who completed treatment less than six weeks ago
+Participants must have histologically confirmed malignancy that is metastatic or currently unresectable; eligible malignancies include:\r\n* Adenocarcinoma of the pancreas (locally advanced or metastatic)\r\n* Colorectal (stage IV)\r\n* Non-small cell lung cancer (currently unresectable stage III or stage IV)
+AJCC stage I - III non-inflammatory, HER2-positive (according to ASCO-CAP guidelines 5) breast cancer
+AJCC Stage IV breast cancer
+Documentation of WHO clinical stage 3 or 4 condition within 6 months of entry
+Patients must have completed curative-intent therapy (including surgery, radiation, and/or chemotherapy) for a first tobacco-related oral premalignant lesion (OPL) or HNSCC of any stage (eligible lesions include high grade dysplasia; carcinoma in situ; or stage I-IVa HNSCC); NOTE: the presence of a measurable OPL at baseline is not required
+Known diagnosis of stage III colon or rectal cancer will be excluded from the study
+Stage II, III, or IV NSCLC for whom radiation therapy of 60 Gy and concurrent weekly paclitaxel/carboplatin is recommended
+End stage renal disease with hemodialysis
+Clinical stage T2c or less
+Pathologic stage T0-T3N0-N1M0
+History of previous malignancies unless the cancer was stage I or II and rendered free of disease more than 1 year
+Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma stage I-IV; (patients should have a > 2 year life expectancy)
+Histologically confirmed stage IV gastrointestinal (GI) cancer (American Joint Committee on Cancer [AJCC] 7th edition) currently sensitive to oxaliplatin containing chemotherapy regimen
+Stage IV or distant metastatic disease
+The patient has diagnosis of stage IV disease or is found to have stage IV disease prior to randomization
+Participants undergoing definitive surgery at diagnosis must have pathologic stage II or III disease
+Participants undergoing preoperative systemic therapy must have clinical stage II or III disease at presentation (clinical stage I disease is excluded)
+History of stage I-III breast cancer
+Subject has metastatic disease (M1) Stage IV-C.
+Has end-stage renal impairment
+Early stage and/or treatment naïve, or
+Primary tumor stage T1-3 at initial diagnosis
+Stage II-IV epidermoid cancer of the head and neck OR stage III-IV pancreatic cancer, with prognosis of at least three months, per oncologist
+Diagnosed with stage I or II pancreatic cancer or with anticipated survival of less than three months
+Pathologically confirmed diagnosis of breast cancer, clinical stage I-II (T1-3 N0 M0, T0-2 N1 M0); diagnosis must be by needle biopsy; patients diagnosed by surgical excision are excluded; for patients enrolled after receipt and completion of neoadjuvant chemotherapy, the clinical stage must be determined based on pre-chemotherapy assessment
+FOR STAGE 2:
+Participants must have biopsy confirmed and clinical stage I, stage II, or stage III noninflammatory breast carcinoma; if biopsy was done at an outside hospital, pathology will be reviewed at (BWH, Brigham and Women's Faulkner Hospital [BWFH])
+Participants must have biopsy confirmed and clinical stage 1 or stage 2 breast carcinoma; if biopsy was done at an outside hospital, pathology will be reviewed at Brigham and Women's Hospital (BWH)/Dana-Farber Cancer Institute (DFCI)
+Pathologically or cytologically confirmed diagnosis of metastatic (stage IV) RAS wildtype CRC
+Patients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIIC
+Patients receiving once daily fractionated intrathoracic radiation therapy for:\r\n* Stage IIA-IIIB non-small cell lung cancer\r\n* Limited stage small cell lung cancer\r\n* Stage I-III esophageal cancer (neoadjuvant or definitive)\r\n** For esophageal patients, accrual will be limited to patients that are NOT receiving trastuzumab
+Have histologic or cytologic biopsy-proven diagnosis of unresectable stage III or distant metastatic melanoma, irrespective of histologic type (i.e. cutaneous, unknown primary, mucosal, or ocular); patients with resectable bulky stage IIIB or stage IIIC melanoma (for example at least 2.5-cm in shortest diameter for lymph nodes infiltrated by tumor and at least 2-cm in longest diameter for non-lymph nodes infiltrated by tumor) can also be entered into the study at the discretion of the principal investigator
+Any tumor stage, any N, M0
+> stage 3 heart failure
+Melanoma tumor that meets indications for a groin SLN biopsy with a >= 10% risk of having metastasis to the draining lymph node (i.e. stage IB to stage IIIC melanoma of the lower body below the umbilicus)
+Clinical stage > T2b or evidence of nodal
+American Joint Committee on Cancer (AJCC) stage I to IV lung cancer requiring radiation therapy (3-dimensional [3D] conformal or stereotactic) or systemic therapy, with or without surgery
+Any stage is eligible
+Patients without known bone metastases who are newly diagnosed with ? stage 3 breast cancer, ? stage 3 lung cancer, or ? stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer
+Subjects with AJCC 7th edition stage TxN0 and M1 disease
+Subjects with AJCC 7th edition stage TxN0, T4b, and M1 disease
+Clinical stage: =< T2a & N0 or NX & M0 or MX
+Melanoma tumor that requires a wide local excision in the operating room; this may include any stage of melanoma from stage IA to stage IV that requires a wide excision in the operating room
+Patients must have pathologically documented advanced NSCLC (stage IV or recurrent)
+Patient’s clinical stage must be documented as tumor size less than 5 cm, with no palpable nodes and no evidence of metastatic disease (T1 or T2 N0 M0); for patients who will receive neoadjuvant systemic therapy, pre-treatment clinical stage should be used
+American Joint Committee on Cancer (AJCC) stage I, II, III or IV non-small-cell lung cancer as well as distant metastasis within the lung to be treated using radiotherapy will be eligible for this study
+Stage IV breast cancer
+Participants with known metastatic (stage IV) prostate cancer
+Patients must be deemed appropriate for doxorubicin-based chemotherapy regardless of individual diagnosis or stage of disease
+Histologically confirmed or suspected stage III or IV high-grade serous ovarian cancer
+Stage I-IV disease\r\n* For patients with stage I-IIIC disease:\r\n** Scheduled for lumpectomy or mastectomy or considered a candidate for therapeutic systemic treatment\r\n** No prior or current therapy for breast cancer \r\n* For patients with stage IV disease: \r\n** Previously untreated for breast cancer with breast mass intact
+Patient has stage IIIB (and is not a candidate for definitive multimodality therapy) or has stage IV NSCLC or relapsed locally advanced or metastatic NSCLC as follows:
+Patients must have stage I or II disease based on the parameters for staging NSCLC found in the American Joint Committee on Cancer (AJCC) cancer staging handbook, seventh (7th) edition
+Patients with a diagnosis of advanced stage disease (stage III or IV)
+Patients must meet one (or more) of the following criteria:\r\n* Preoperative diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma (all stage, grade and histology)\r\n* Preoperative diagnosis of grade III endometrial carcinoma (all stage, all histology)\r\n* Preoperative diagnosis of uterine serous carcinoma (all stage, all grade)\r\n* Preoperative diagnosis of clear cell endometrial carcinoma (all stage, all grade)\r\n* Preoperative diagnosis of endometrial carcinosarcoma (all stage, all grade)\r\n* Gastrointestinal carcinoma (all histology, stage and grade)\r\n* Pancreatic carcinoma (all histology, stage and grade)\r\n* Lung cancer (all histology, stage and grade)\r\n* Esophageal carcinoma (all histology, stage and grade)\r\n* Suspected or pathologically confirmed metastatic disease to the lung (all disease primaries)\r\n* Suspected or pathologically confirmed malignant pleural effusion (all disease primaries)
+Patients who have bladder tumors of stage >= T3; or
+Subjects must be diagnosed with histologically proven stage IV (metastatic) melanoma or stage III with bulky disease which may or may not be amenable for surgery and are receiving therapy at present
+Subjects must be classified as TNM stage I, II, or III; alternatively, subjects may be classified as Barcelona Clinic Liver Cancer (BCLC) stage A or B
+Patient must have stage IIIA non-small cell lung cancer (T1-3N2) per American Joint Committee on Cancer (AJCC) 7th edition and must be considered to be surgically resectable
+Eligible patients must have appropriate staging studies identifying them as specific subsets of American Joint Committee on Cancer (AJCC) 7th edition stage I or II based on only one of the following combinations of tumor, nodes, metastatic (TNM) staging:\r\n* T1a-b, N0, M0\r\n* T2a, N0, M0\r\n* T3 (invading the chest wall, < 5 cm in diameter) N0 M0
+Pathological T3 stage of disease (i.e., EPE or SVI), or
+Patient must have clinical American Joint Committee on Cancer, 6th edition stage II or III breast cancer and be considered a candidate for curative mastectomy
+No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer
+Prior systemic therapy, radiotherapy, or investigational agent in participants undergoing surgery for stage I, II, or III colon cancer
+Subjects with unresectable Stage III or IV melanoma who are either refractory or intolerant to, or have refused standard therapy for treatment of metastatic melanoma
+All patients with early stage (stage I-III) non-small cell lung cancer, adenocarcinoma histology
+A treatment plan involving levels I-III, I-IV, II-III, or II-IV, as recommended by National Comprehensive Cancer Network (NCCN) guidelines
+For stage IV disease:\r\n* Scheduled for surgical resection of oligometastatic disease\r\n* Previously untreated for breast cancer
+locoregional OSCC (T stage II-IV) of the oral cavity, oropharynx, larynx, or hypopharynx without evidence of distant metastases
+Stage IV breast cancer
+On average, cares for at least 3 AA patients with early stage NSCLC per year (based on the last 3 years of cancer registry data)
+Locally advanced (stage IIIA-IIIB) or metastatic (stage IV) NSCLC
+Diagnosed with stage IV breast cancer within the past 3 years
+Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group [ECOG] performance status, and any NSCLC – adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;\r\n* Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)
+Newly diagnosed patients for the following conditions\r\n* Colon cancer stage III and IV\r\n* Rectal cancer stage II, III, IV\r\n* Glioblastoma multiforme (brain) -- no stage\r\n* Non-small cell lung cancer stage IIIA, IIIB, IV\r\n* Small cell lung cancer, limited stage and extensive stage\r\n* Castration-resistant prostate cancer\r\n* Head and neck cancer stage III and IV\r\n* Gastric cancer stage III and IV\r\n* Esophageal cancer stage III and IV\r\n* Pancreatic cancer stage II, III, IV\r\n* Renal cell carcinoma, stage IV\r\n* Breast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic chemotherapy\r\n* Sarcoma, stage IV\r\n* Bladder carcinoma, stage IV\r\n* Acute myeloid leukemia\r\n* Melanoma, stage III and IV\r\n* Ovarian cancer, stage III and IV\r\n* High grade myelodysplastic syndrome (MDS)
+American Joint Committee on Cancer (AJCC) stage 1, 2, 3 breast carcinoma
+First diagnosis with stage 1-2 breast or stage 1-2 lung cancer; and voluntary participation
+AND diagnosed with Stage I-III incident breast or colorectal cancers;
+Patients with in situ cancers (Stage 0) and those with metastatic disease (Stage IV);
+Cancer Registry cases include stage I-III colon cancer (adenocarcinoma histology), stage I-III rectal cancer (adenocarcinoma histology), stage I-III non-small cell lung cancer (squamous or adenocarcinoma histology)
+Stage IV cancer or evidence of metastatic disease at any time point
+Stage 4 patients are not eligible
+Clinical stage < cT3
+Adequately treated Stage I or II cancer from which the subject is currently in complete remission
+stage II-III, planned to be treated with radical surgery
+Has histologically confirmed, unresectable Stage III or Stage IV melanoma per the American Joint Committee on Cancer (AJCC) staging system.
+Known Stage IV ovarian cancer with Brain Metastases
+End-stage renal disease (ESRD) on hemodialysis or CrCl ? 75 mL/min
+Locally advanced or metastatic (stage IIIB, stage IV, or recurrent) NSCLC with measurable lesions per RECIST version 1.1.
+Histologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
+Clinical stage: T3/T4
+American Joint Committee on Cancer (AJCC) 7th edition (ed.) stage cN0 or cN1 subsequently staged after surgery as stage pIB (N1mic), pIIA, pIIB, pIIIA, pIIIB, or N3a (10 or more axillary nodes) only: note that ypN0 will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node negative at the time of surgery; note that women less than 50 years of age, women who received chemotherapy, patients staged as pN0 (i+ or mol+), and large-breasted women are eligible for enrollment
+Histologically or cytologically confirmed stage IV (metastatic) NSCLC as defined by American Joint Committee on Cancer (AJCC); recurrent but not metastatic disease is allowed if deemed incurable
+Clinical stage T2-T4a, N0, M0 urothelial bladder cancer